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Abstract
This paper reports on the consensus conference on the management of intra-abdominal infections (IAIs) which was
held on July 23, 2016, in Dublin, Ireland, as a part of the annual World Society of Emergency Surgery (WSES) meeting. This
document covers all aspects of the management of IAIs. The Grading of Recommendations Assessment, Development
and Evaluation recommendation is used, and this document represents the executive summary of the consensus
conference findings.
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Background
Intra-abdominal infections (IAIs) are an important cause
of morbidity and mortality [1]. Early clinical diagnosis,
adequate source control to stop ongoing contamination,
appropriate antimicrobial therapy dictated by patient
and infection risk factors, and prompt resuscitation in
critically ill patients are the cornerstones in the manage-
ment of IAIs. However, several critical controversies can
be debated in the management of these patients. Appli-
cation of management principles to the individual pa-
tient is crucial to optimize outcome. In order to clarify
these major controversies in the management of IAI,
many of the world’s leading experts met in Dublin,
Ireland, on July 23, 2016, for a specialist multidisciplinary
consensus conference under the auspices of the World
Society of Emergency Surgery (WSES) and with the sup-
port of the World Society of Abdominal Compartment
Syndrome (WSACS). This document represents the ex-
ecutive summary of this consensus conference.
Methodology
In constituting the expert panel, the WSES committee
invited many of the world’s leading experts in the man-
agement of IAIs. It was a multidisciplinary expert panel
including general and specialist surgeons, emergency
and acute care surgeons, infectious disease specialists,
and intensivists. The expert panel reviewed the scientific
evidence and composed statements which addressed a
set of predefined questions.
The statements were formulated and graded according
to the Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) hierarchy of evidence from
Guyatt and colleagues [1], summarized in Table 1.
During the WSES annual conference which was held
in Dublin, the statements were debated and approved by
the committee jury panel. This document represents the
executive summary of the final recommendations
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approved by the consensus conference. The document
was reviewed and approved by both the expert and
jury panels.
What is the most appropriate classification for
intra-abdominal infections?
Statement 1
The term “intra-abdominal infections” describes a
wide heterogeneity of clinical conditions. The anatom-
ical extent of infection, the presumed pathogens in-
volved, risk factors for major resistance patterns, and
the patient's clinical condition should be assessed in-
dependently so as to classify patients (Recommenda-
tion 1 C).
A complete classification that includes the origin of
source of infection, the anatomical extent of infection,
the presumed pathogens involved and risk factors for
major resistance patterns, and the patient’s clinical con-
dition does not exist.
A simple and universally accepted classification divides
IAIs into complicated and uncomplicated [2]. In the
event of uncomplicated IAIs, the infection only involves
a single organ and does not extend to the peritoneum.
When the focus of infection is controlled by surgical ex-
cision, post-operative antibiotic therapy is not necessary
[3–5]. In the event of complicated IAIs (cIAIs), the infec-
tious process proceeds beyond the organ into the periton-
eum, causing either localized or diffuse peritonitis.
Treatment of patients with cIAIs involves generally
both source control, antibiotic therapy, and potentially
novel therapies targeted at modulating or ameliorating
the host inflammatory response. Antibiotics can prevent
local and hematogenous spread and can reduce late
complications [6].
This classification has been questioned by some au-
thors because it often has incited confusion by mixing
elements of anatomical barrier disruption and severity of
disease expression [7].
Peritonitis is an inflammation of the peritoneum.
Depending on the underlying pathology, it can be infec-
tious or sterile. Infectious peritonitis is classified into
primary peritonitis, secondary peritonitis, and tertiary
Table 1 Grading of Recommendations Assessment, Development and Evaluation (GRADE) hierarchy of evidence from Guyatt and
colleagues [1]
Grade of recommendation Clarity of risk/benefit Quality of supporting evidence Implications
1A
Strong recommendation,
high-quality evidence
Benefits clearly outweigh risk
and burdens, or vice versa
RCTs without important limitations
or overwhelming evidence from
observational studies
Strong recommendation,
applies to most patients in
most circumstances without
reservation
1B
Strong recommendation,
moderate-quality evidence
Benefits clearly outweigh risk
and burdens, or vice versa
RCTs with important limitations
(inconsistent results, methodological
flaws, indirect analyses or imprecise
conclusions) or exceptionally strong
evidence from observational studies
Strong recommendation,
applies to most patients in
most circumstances without
reservation
1C
Strong recommendation,
low-quality or very low-quality
evidence
Benefits clearly outweigh risk
and burdens, or vice versa
Observational studies or case series Strong recommendation but
subject to change when higher
quality evidence becomes
available
2A
Weak recommendation,
high-quality evidence
Benefits closely balanced with
risks and burden
RCTs without important limitations or
overwhelming evidence from
observational studies
Weak recommendation, best
action may differ depending
on the patient, treatment
circumstances, or social values
2B
Weak recommendation,
moderate-quality evidence
Benefits closely balanced with
risks and burden
RCTs with important limitations
(inconsistent results, methodological
flaws, indirect or imprecise) or
exceptionally strong evidence from
observational studies
Weak recommendation, best
action may differ depending
on the patient, treatment
circumstances, or social values
2C
Weak recommendation,
Low-quality or very low-quality
evidence
Uncertainty in the estimates
of benefits, risks, and burden;
benefits, risk, and burden may
be closely balanced
Observational studies or case series Very weak recommendation;
alternative treatments may be
equally reasonable and merit
consideration
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peritonitis [2]. Primary peritonitis is a diffuse bacterial
infection (usually caused by a single organism) without
loss of integrity of the gastrointestinal tract, typically
seen in cirrhotic patients with ascites or in patients with
a peritoneal dialysis catheter. It has a low incidence on
surgical wards and is usually managed without any surgi-
cal intervention. Secondary peritonitis, the most com-
mon form of peritonitis, is an acute peritoneal infection
resulting from loss of integrity of the gastrointestinal
tract. Tertiary peritonitis is a recurrent infection of the
peritoneal cavity that occurs >48 h after apparently
successful and adequate surgical source control of
secondary peritonitis. It is more common among critic-
ally ill or immunocompromised patients and may be
often associated with multidrug-resistant organisms
(MDROs). It is typically associated with high morbidity
and mortality. Tertiary peritonitis has been accepted as a
distinct entity. However, it represents an evolution and
complication of secondary peritonitis [8–10]. The term
“ongoing peritonitis” [11] or “persistent peritonitis” [12]
may better indicate that it is not a different disease to
secondary peritonitis, but rather represents secondary
peritonitis lasting longer and harboring other (selected
and more resistant) pathogens.
The term “healthcare-associated infection” (HCAI) is a
new term for infections acquired during the course of
receiving healthcare. It includes not only hospital-
acquired infections but also infections in patients living
in nursing facilities, having recent hospitalization within
90 days, and using aggressive medical therapies (intra-
venous therapy, wound dressing) at home and invasive
therapies (hemodialysis, chemotherapy, radiotherapy) in
outpatient clinics within 30 days of the index infection
[13]. In the setting of IAIs, there is relatively little data re-
garding the concept of healthcare-associated infections as
opposed to hospital-acquired or nosocomial infections.
Differentiating community-acquired intra-abdominal in-
fections (CA-IAIs) from hospital-acquired intra-abdominal
infections (HA-IAIs) is useful to define the presumed re-
sistance patterns and identify patients with increased likeli-
hood of infection caused by MDROs.
Among patients with HA-IAIs, those with post-operative
peritonitis may be associated with increased mortality due
to underlying patient comorbidity, atypical presentation
due to non-specific clinical signs, and risk factors for ac-
quiring MDROs and Candida spp. infections [14–16].
Grading of the clinical severity of patients with cIAIs
has been well described by the sepsis definitions [17]. The
data from WISS study showed that mortality was signifi-
cantly affected by sepsis status when divided into four
categories. Mortality rates increase in patients developing
organ dysfunction and septic shock. Mortality by sepsis
status was as follows: no sepsis 1.2%, sepsis only 4.4%, se-
vere sepsis 27.8%, and septic shock 67.8% [18].
Recently, the third International Consensus Definitions
for Sepsis and Septic Shock (Sepsis-3) were published
[19], replacing previous classifications [20, 21]. Sepsis is
now defined as a life-threatening organ dysfunction
caused by a dysregulated host response to infection.
Organ dysfunction can be represented by an increase in
the Sequential [sepsis-related] Organ Failure Assessment
(SOFA) score of 2 points or more. Septic shock should
be defined as a subset of sepsis and should be clinically
identified by a vasopressor requirement to maintain a
mean arterial pressure of 65 mmHg or greater and
serum lactate level greater than 2 mmol/L in the absence
of hypovolemia.
Designing a classification which is accepted world-
wide may be important to stratify patients according to
the risk for antimicrobial therapy failure. A new classifi-
cation would permit uniform regimens for patients hav-
ing cIAIs and increase the comparability of studies
carried out at different centers.
What are the optimal methods in diagnosing IAI
that balances benefits and risks?
Statement 2
Early clinical evaluation is essential for diagnosing
IAIs. It helps to optimize diagnostic testing and can
result in earlier implementation of a proper manage-
ment plan (Recommendation 1C).
Statement 3
A step-up approach for diagnosis should be used and
tailored to the clinical setting, resources, patient’s age
beginning with clinical and laboratory examination
and progressing to imaging examinations (Recommen-
dation 1C).
Diagnosis of complicated IAIs is mainly clinical. Early de-
tection and treatment is essential to minimize complica-
tions of IAIs [22, 23].
Patients with IAIs typically present with rapid-onset
abdominal pain and signs of local and systemic inflamma-
tion (pain, tenderness, fever, tachycardia, and/or tachypnea).
Hypotension and hypoperfusion signs such as oliguria,
acute alteration of mental status, and lactic acidosis are in-
dicative of ongoing organ failure.
Physical evaluation may limit the differential diagnosis
to direct decisions regarding a proper management plan
including the need for appropriate diagnostic testing, the
need for initiation of antimicrobial therapy, and whether
emergent intervention is required [22].
The value of physical findings in the diagnostic
work-up for IAIs has been studied in relation to acute
appendicitis where signs and symptoms are helpful in
diagnosing or excluding appendicitis [24].
The presence of a positive psoas sign, fever, or migra-
tory pain to the right lower quadrant suggests an
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increased likelihood of appendicitis. Conversely, the
presence of vomiting before pain makes appendicitis un-
likely [25].
Ultrasound (US) and computed tomography (CT) have
been used over the last two decades to complete the
clinical assessment of patients with IAIs. Although CT
has higher sensitivity and specificity [26], concerns about
radiation exposure have recently prompted reappraisal
of the roles of sonography [27] including performance
by surgeons [28].
Proposals of staged algorithms using a step-up ap-
proach with CT performed after an inconclusive or
negative US have been proposed in the setting of acute
appendicitis and acute diverticulitis [29–32].
Magnetic resonance imaging (MRI) is not routinely
available in most hospitals in the emergency setting. It
has been proposed to be used in pregnant patients with
abdominal pain when US is inconclusive [33]. Recently,
a systematic review and meta-analysis of diagnostic per-
formance of MRI for evaluation of acute appendicitis
was published [34]. A total of 30 studies that comprised
2665 patients were reviewed. The sensitivity and specifi-
city of MRI for the diagnosis of acute appendicitis was
94% (95% CI, 87–98%) and 96% (95% CI, 95–97%),
respectively.
Laparoscopy is gaining wider acceptance in emergency
surgery [35]. When imaging has been unhelpful, diag-
nostic laparoscopy may be used to identify the causative
pathology of acute abdominal pain followed by definitive
laparoscopic treatment. The accuracy of diagnostic lapar-
oscopy is very high reporting definitive diagnosis rates
between 86 and 100% in unselected patients [36, 37].
Which patients are at high risk of failure?
Statement 4
Patient factors are essential when addressing treat-
ment outcome, as advanced age, associated comor-
bidity, pre-existing disease, and physiologic status
greatly influence outcomes (e.g., mortality) (Recom-
mendation 2 C).
Statement 5
Disease factors are essential to consider when
addressing risk for treatment failure. (Recommen-
dation 2 C).
Statement 6
While age alone is not decisive for outcome it
should be recognized that patients with an accu-
mulated number of risk factors, including ad-
vanced age, high disease severity and presenting
in sepsis or septic shock, have a very high risk of
death. Palliative care should be actively discussed
when conditions indicate that operative treatment
is futile (Recommendation 2 C).
Defining the patient with IAIs at high risk for failure is
difficult. First, it depends on the definition of failure as
an outcome; is this mortality? failure of surgical source
control? failure of antibiotic control? Various studies use
variable definitions of outcome.
Second, “high risk” may be attributed to the patient’s
underlying condition(s), such as age, comorbidity or the
disease severity status on presentation. In addition, a
“low-risk” patient may be converted to “high risk” if the
care provider loses the “window of opportunity” to diag-
nose, resuscitate, and start timely treatment. Thus, there
are numerous situations that must be taken into account
when addressing high-risk patients and treatment failure.
In general, high-risk IAI is attributed to patient factors
(advanced age, immunosuppression, malignant disease,
and pre-existing medical comorbidities) or disease factors,
represented by high-risk scores (such as ASA, APACHE,
SOFA scores), delay in intervention (usually >24 h), inabil-
ity to obtain source control, and an IAI that is healthcare
associated (rather than community acquired) [38].
While age alone is not decisive for outcome, it should
be recognized that elderly patients are at high risk for
adverse outcomes, including death [39]. Core to the as-
sociated poor outcomes is the reduced physiological re-
serve and limited response to any minor or major
stressor that comes with age [40] and which is summa-
rized in the concept of “frailty” [41]. While frailty can be
readily defined [41, 42], it is difficult to measure in the
emergency setting, although attempted by several recent
approximated measures [43–46]. In particular, patients
with IAIs and pre-existing malignant disease have a par-
ticular high risk for a poor outcome [47, 48].
Disease severity on presentation is strongly associated
with risk of failure or poor outcome, including death.
The risk is in large part disease-dependent (e.g., lower
with appendicitis than for perforated gastroduodenal
ulcer); thus, the use of one generic risk score may not be
sufficient. For all IAIs, the presence of sepsis or septic
shock is a generic prognostic feature and defines a disease
process that has become systemic, rather than a localized
disease process. Several disease specific scores exist for
various organ-related IAIs (appendicitis, diverticulitis, per-
forated ulcers) [49–52], for which none have good accur-
acy, prediction ability, nor validity and generalizability.
Pre-admission functional status should be considered
[53]; compared to an independent status, nursing home
residents have a several-fold increased risk for adverse
outcomes, including death.
Patients with an accumulated number of risk factors,
including very high age and high disease severity and
presenting in sepsis or septic shock, have an excessively
high risk of death. The appropriateness of advanced, par-
ticularly invasive treatment versus palliative measures
should be actively discussed [54, 55].
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Are prognostic scores useful in clinical practice?
Statement 7
Prognostic scoring systems for complicated IAIs
may be useful in clinical practise, especially for audit
and research. Scoring systems can be broadly divided
into two groups: general organ failure severity (ICU)
scores and peritonitis-specific (Surgical) scores. The
Sequential Organ Failure Assessment (SOFA) score
allows physicians to follow the evolving disease
process in critically ill patients in ICU (Recommen-
dation 2 A).
However, although these scores may help guide clinical
care, their use in individual patients is much less
predictive.
Early prognostic evaluation of cIAIs is important to as-
sess the severity and the prognosis of the disease. It
would be valuable to have accurate prognostic scores in
IAIs for a variety of reasons which include (1) prediction
of prognosis and (2) selection of treatment options/help
guide management strategies and allow (3) comparative
audit and (4) research, i.e., stratification in clinical trials.
Scoring systems can be broadly divided into two
groups:
1. General Organ Failure Severity (ICU) scores
2. Peritonitis-Specific (Surgical) scores
General Organ Failure Severity (ICU) scores
These scores are used in the ICU and can allow con-
tinuous assessment of medical and surgical patients.
Over the past years, many scoring models have been
developed to describe the severity of illness of intensive
care patients or to predict the outcome of intensive
care treatment. Some require computer-aided calcula-
tions and the input of complex variables, whereas
others are more simple. The majority of scores assess
various organ systems for the presence of dysfunction
(respiratory, hemodynamic, renal, neurological, bio-
chemical, coagulation) and are used in sepsis and other
general causes of multiorgan failure.
Severity of illness scoring systems such as the full
APACHE II or the Simplified Acute Physiology Score
(SAPS) are based on the parameters of the first 24 h of
ICU stay and may be applicable also in patients with
peritonitis [56]. The SOFA score is a simple and objective
severity score that allows both calculation of the number
and the severity of organ dysfunction in six organ systems
(respiratory, coagulation, liver, cardiovascular, renal, and
neurologic) [57]. The SOFA scoring system also tracks the
time course of a patient’s condition during the entire ICU
stay. Regular, repeated scoring enables patient condition
and disease progression to be monitored and better
understood. It allows physicians to follow the evolving
disease process in critically ill patients [58].
Peritonitis-Specific (Surgical) scores
These scores are calculated as a one off at the time of
surgery and often include intra-operative features of the
extent of contamination. Surgical scores can be disease
specific; for example, the left-sided colonic Peritonitis
Severity Score (PSS) [59]. There are also many scoring
systems for perforations of gastroduodenal ulcers, in-
cluding the Boey Score, Jabalpur Index, Hacettepe Score,
and PULP Score [52, 60, 61]. Prognostic scores which
can be universally used in a variety of etiologies, include
the P-POSSUM, Mannheim Peritonitis Index (MPI),
Peritonitis Index Altona (PIA) [62], and WSES compli-
cated IAI score from the WISS study [18]. The MPI
score is easy to calculate, even during surgery. It is cal-
culated using simple factors such as degree of periton-
itis, age, sex, time from perforation to operation, origin
of sepsis, kind of exudates (clear, purulent, or fecal) [63].
Billing et al. demonstrated the reliability of MPI in 2003
patients from seven centers in Europe showing that it is
an easy and reliable means of risk evaluation and classifi-
cation for patients with peritonitis [63].
The WISS study is a multicenter prospective study of
4533 patients published in 2015 [18] specifically to valid-
ate the WISS score, which was built on the previous work
of the CIAO and CIAOW studies. The WSES/WISS score,
estimated at the admission of the patients, includes factors
for (1) clinical condition on admission, (2) setting of ac-
quisition, (3) delay in source control, and (4) risk factors
including age and immunosuppression. Scores can range
from 0 to ≥18. A score above 5.5 was the best predictor of
mortality with a sensitivity of 89.2% and specificity of
83.5% (a positive likelihood ratio of 5.4).
However, while all these scores are useful tools for re-
search studies, they are not sufficiently accurate to pre-
dict individual patient prognosis. Although it is hoped
that these scores may help guide management decisions
in the future, at the present time, they are principally
used for comparative surgical audit and research tools.
What is the utility of source control? When should
source control be undertaken? Is source control
necessary in all patients with cIAI? What
approaches should be utilized for source control?
Statement 8
Most patients with cIAIs and sepsis/septic shock
should undergo an urgent source control procedure;
source control can be delayed in less severely-ill pa-
tients when the circumstances are appropriate (Rec-
ommendation 2 C).
Source control encompasses all the measures under-
taken to eliminate the source of infection and to control
ongoing contamination. Timing and adequacy of source
control are currently the most important issues in the
management of IAIs because inadequate and late
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operation may have a negative effect on outcome [64–
69]. The optimal timing of source control has not been
rigorously investigated. SIS/IDSA guidelines suggest that
source control should be performed as soon as possible
in patients with diffuse peritonitis but that intervention
could be delayed for logistical reasons as long as 24 h in
patients with a localized infection if appropriate anti-
microbial therapy is given and careful clinical monitor-
ing is provided [22].
In a review by De Waele, source control was consid-
ered an essential element in the management of sepsis
and should be considered and performed early after the
diagnosis is established in most if not all patients [70].
The 2016 Surviving Sepsis Campaign guidelines suggest
that a specific anatomic diagnosis of infection requiring
emergent source control should be identified or ex-
cluded as rapidly as possible in patients with sepsis or
septic shock [71].
Sotto et al. in 2002 found in a retrospective study that
time between diagnosis and operation was associated
with mortality [72]. In this study, the period between
diagnosis and surgery (P = 0.04) was predictive of death
within 30 days after diagnosis of peritonitis emphasizing
the importance of prompt surgical treatment. In another
retrospective review of 129 patients [73] with non-
traumatic severe intra-abdominal infections, multivariate
analysis identified that an operating room latency of
60 h or longer (P = 0.01) was a predictor of need for
relaparotomy.
Statement 9
Highly selected patients with perforated diverticulitis
(including those with an abscess <4 cm in diameter), a
peri-appendiceal mass, or a perforated peptic ulcer can
be managed without definitive source control if
responding satisfactorily to antimicrobial therapy and
other supportive measures. (Recommendation 1 B).
An operative intervention remains the most viable
therapeutic strategy for managing intra-abdominal
sepsis. Surgical source control entails resection or su-
ture of a diseased or perforated viscus (e.g., diverticu-
lar perforation, gastroduodenal perforation), removal
of the infected organ (e.g., appendix, gallbladder), de-
bridement of necrotic tissue, resection of ischemic
bowel, and repair/resection of traumatic perforations
with primary anastomosis or exteriorization of the
bowel.
However, some data indicate highly selected pa-
tients can be managed without definitive source
control if responding satisfactorily to antimicrobial
therapy alone.
In addition, well-localized fluid collections of appropri-
ate density and consistency (i.e., lack of extensive locula-
tions) may be drained percutaneously with acceptable
morbidity and mortality [74–78].
Approximately 15–20% of patients admitted with
acute diverticulitis have an abscess on CT scan [79].
These abscesses may be initially treated by intraven-
ous antibiotics alone with or without percutaneous
drainage, depending on the size of the abscess. A
maximum diameter of 3–6 cm has been generally ac-
cepted as a reasonable limit for treatment with anti-
microbial therapy alone without drainage [80, 81].
Although the absolute prevalence of perforated diver-
ticulitis complicated by generalized peritonitis is low, it
has a significant post-operative mortality, regardless of
selected surgical strategy. However, CT findings of
distant free air (a known predictor of failure of non-
operative treatment) does not necessarily obligate a sur-
gical approach. Dharmarajan et al. [82] described a high
success rate for non-operative management in patients
with acute diverticulitis and a pneumoperitoneum, ex-
cluding those with hemodynamic instability.
Sallinen et al. [83] reported results of non-operative
management in patients with CT verified extra-luminal
air. This study showed that non-operative treatment was
feasible therapy only for hemodynamically stable pa-
tients with CT findings of pericolic extra-luminal air or
only a small amount of distant intraperitoneal air in the
absence of clinical diffuse peritonitis or fluid in the fossa
of Douglas. A large amount of distant intraperitoneal air
or distant retroperitoneal air even in the absence of clin-
ical generalized peritonitis was associated with a high
failure rate (57–60%) of non-operative management.
Recent WSES guidelines for management of acute left
colonic diverticulitis [84] state that patients with CT
findings of distant air without diffuse fluid may be
treated by conservative treatment in selected cases; how-
ever, a risk of treatment failure and need for emergency
surgery exists.
Antibiotics alone may be used to treat patients with
early, non-perforated appendicitis, although there is a
significant risk of subsequent recurrence [85].
In patients with complicated appendicitis, presenting
with abscess or phlegmon, the optimal management
strategy has been somewhat controversial. Several stud-
ies have found that non-operative treatment for a peri-
appendiceal abscesses or masses results in fewer compli-
cations and shorter overall hospitalization [86–88].
In 2010, a meta-analysis [89] was published comparing
conservative treatment (i.e., antibiotic therapy with or
without percutaneous abscess drainage) to appendectomy
for the treatment of complicated appendicitis (cases
exhibiting abscess or phlegmon). Seventeen studies (16
non-randomized/retrospective and one non-randomized/
prospective) reported clinical data for 1572 patients of
whom 847 patients received conservative treatment and
725 underwent acute appendectomy. Conservative treat-
ment was associated with significantly fewer complications,
Sartelli et al. World Journal of Emergency Surgery  (2017) 12:22 Page 6 of 31
wound infections, abdominal/pelvic abscesses, ileus, bowel
obstruction, and additional follow-up surgeries. No signifi-
cant differences were found in the overall length of
hospitalization or in the duration of intravenous antibiotic
infusion. Overall, clinical data supports the utility of
conservative management rather than appendectomy in se-
lected patients presenting with a peri-appendiceal abscess
or phlegmon.
Although the widespread clinical use of H2 receptor
antagonists, proton-pump inhibitors (PPI), and antibiotic
therapy directed against Helicobacter pylori has greatly
reduced surgical treatment of peptic ulcer disease in re-
cent years, complications, especially perforation, are still
frequently seen. Non-operative management of perfo-
rated peptic ulcer (PPU) may be an option, although
urgent repair of perforation is still the standard approach
for PPU in many clinical centers. Several studies have in-
dicated that patients with PPU can be successfully
treated non-operatively [90–93]. Non-operative manage-
ment includes the use of nasogastric drainage, supportive
care (IV fluids and nutrition), intravenous antibiotics,
intravenous PPI, and radiological drainage of intra-
abdominal collections.
The 2013 WSES guidelines for management of IAIs
[94] state that in selected cases (age <70 years, no shock,
no peritonitis, lack of spillage of the water-soluble con-
trast medium on gastroduodenogram), non-operative
management is an option. However, if no improvement
of the patient’s condition is observed within 24 h, surgi-
cal therapy is indicated.
What are the indications for laparoscopic
approach to IAIs?
Laparoscopic procedures have become widely accepted
by the medical community as a primary means of diag-
nosing and treating IAIs. On the basis of the anatomical
source of infection and the attending surgeon’s experience,
laparoscopy may be recommended for the treatment of
many IAIs [95].
Statement 10
Laparoscopic appendectomy represents the first
choice for most patients with acute appendicitis
where appropriate resources and skills are available
(Recommendation 1 A).
Recent WSES guidelines for diagnosis and treatment
of acute appendicitis stated that laparoscopic appendec-
tomy (LA) is the first choice where laparoscopic equip-
ment and skills are available [96]. In the Sauerland et al.
review, wound infections were less likely after LA than
after open appendectomy (OA) (OR 0.43; CI 0.34–0.54);
however, the incidence of intra-abdominal abscesses was
increased (OR 1.87; CI 1.19–2.93) [97]. Despite evidence
showing that LA is safe in pregnancy, advantages are
minor (less pain, less infections, less early deliveries) if
compared to the risk of fetal loss. Recent data from re-
views of comparative studies [98] (599 LA versus. 2816
OA) showed an increased fetal loss for LA, without
significant advantages. A population-based analysis on
859 pregnant women [99] with appendicitis confirmed
a better outcome for those treated surgically versus
non-operative management, while it found no difference
in maternal complications between LA and OA. The role
of antibiotic treatment instead of surgical removal for
acute early uncomplicated appendicitis is currently
unknown.
Statement 11
There is no evidence of any significant advantages
between laparoscopic and open repair of perforated
peptic ulcer (PPU). However, laparoscopy has less
postoperative pain and shorter hospital stay (Recom-
mendation 1 A).
Aside from reduced post-operative analgesic demands,
the post-operative outcome of the laparoscopic approach
does not differ significantly from that of open surgery. In
all reported studies, patients presented with small ulcers
and received simple sutures, while many also received
an omental patch. There were no studies reporting
emergency laparoscopic resection or laparoscopic repair
of large ulcers.
A systematic review was published in 2013 [100] in-
cluding randomized clinical trials comparing laparo-
scopic surgery versus open surgery for the repair of
perforated peptic ulcer using any mechanical method of
closure (suture, omental patch, or fibrin sealant).
The authors concluded that laparoscopic surgery results
are not clinically different from those of open surgery, but
there is clearly a selection bias in the studies performed to
date and there is a need of more randomized controlled
trials with a larger number of patients.
Statement 12
Early laparoscopic cholecystectomy is safe and
feasible in acute cholecystitis and should be the pre-
ferred choice in absence of contraindications to
pneumoperitoneum, even in high risk patients,
where appropriate resources and skills are available
(Recommendation 1A).
Recent 2016 WSES guidelines for the management
of acute calculous cholecystitis (AAC) [101] stated that
cholecystectomy is the gold standard for treatment of
ACC. Laparoscopic approach should initially be
attempted except in cases of absolute anesthesiology
contraindications or septic shock. Many prospective
trials have demonstrated that the laparoscopic chole-
cystectomy is a safe and effective treatment for ACC
[102–106]. A recently published meta-analysis demon-
strated that laparoscopic cholecystectomy in ACC
[107] is the preferred approach having lower mortality
and morbidity, significantly shorter post-operative
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hospital stay, and reduced rate of pneumonia and
wound infections, compared with the open technique.
Conversion rate ranged from 8 to 35%.
Statement 13
Laparoscopic lavage is not recommended in
Hinchey IV diverticulitis because it can not achieve
adequate source control. Laparoscopic lavage is safe
and not inferior to sigmoid resection in case of
Hinchey III but it is not considered the preferred
choice, given the lack of evidence of major benefits
(Recommendation 1A).
Statement 14
Laparoscopic sigmoid resection is feasible and safe in
selected patients, hemodynamically stable, without
significant comorbidities and with onset of peritonitis
<12-24 hours, only if specific advanced laparoscopic
colorectal expertise is available (Recommendation 2 C).
A conservative approach using laparoscopic peritoneal
lavage and drainage has been debated in recent years as an
alternative to colonic resection. Great debate is still open
on this topic, mainly due to the discrepancy and sometime
disappointing results of the latest prospective trials such as
SCANDIV, Ladies, and DILALA trials [108–110].
A recent meta-analysis showed that laparoscopic
lavage is a safe procedure in terms of mortality but is
associated with a higher intra-abdominal abscess and re-
operation rate during the index admission. No definitive
high-level conclusions could be drawn by the available
literature at this moment, and further evidence is needed
to better define the role of laparoscopic lavage in the
management of acute perforated diverticulitis with puru-
lent peritonitis [111].
Recent WSES guidelines for the management of acute
diverticulitis in the emergency setting [84] stated that
considering the conflicting results laparoscopic lavage as
treatment for patients with perforated diverticulitis,
Hinchey III disease, may be feasible even if it cannot be
considered the treatment of choice.
Laparoscopic sigmoidectomy for diverticulitis has ini-
tially been confined to the elective setting. However, lap-
aroscopic sigmoidectomy may be feasible for diverticular
peritonitis in the emergency setting also in early cases of
type IV diverticulitis. In 2016, a systematic review on
laparoscopic sigmoidectomy for diverticulitis in the
emergency setting was published [112]. The review in-
cluded only a small number of patients from four case
series and one cohort study (total of 104 patients). High-
quality prospective or randomized studies are needed to
demonstrate benefits of acute laparoscopic sigmoi-
dectomy compared with open sigmoidectomy for per-
forated diverticulitis.
Which is the best relaparotomy strategy?
Statement 15
Planned relaparotomy is not recommended as a
general strategy in patients with secondary peri-
tonitis (Recommendation 1A).
Some patients are prone to persisting IAIs regardless
of eradication of the source of infection and timely
relaparotomy provides the only surgical option that sig-
nificantly improves outcome. In these cases, single oper-
ation may not be sufficient to achieve source control;
thus, relaparotomy may become necessary [113, 114]. In
2007, van Ruler and the Dutch peritonitis group [115]
published a randomized, clinical trial addressing two as-
pects of closed abdominal management, comparing an
on-demand versus planned relaparotomy strategy in pa-
tients with severe peritonitis who had the fascia formally
closed after the initial laparotomy.
In this trial, a total of 232 patients with severe IAIs (116
on-demand and 116 planned) were randomized. In planned
relaparotomy group, relaparotomies were performed every
36 to 48 h after the index laparotomy to inspect, drain, lav-
age, and perform other necessary abdominal interventions
for residual peritonitis or new infectious focus. In on-
demand relaparotomy group, relaparotomies were only per-
formed in patients with clinical deterioration or lack of clin-
ical improvement with a likely intra-abdominal cause.
Patients in the on-demand relaparotomy group did not
have a significantly lower rate of adverse outcomes com-
pared with patients in the planned relaparotomy group but
did have a substantial reduction in relaparotomies, health-
care utilization, and medical costs. Patients in the on-
demand group had shorter median ICU stays (7 versus
11 days; P = 0.001) and shorter median hospital stays (27
versus 35 days; P = 0.008). Direct medical costs per patient
were reduced by 23% using the on-demand strategy.
When and how do you perform a damage control
surgery strategy in patients with severe cIAIs?
Statement 16
There is insufficient evidence to advocate damage
control surgery as general strategy in patients with
secondary peritonitis (Recommendation 1 C).
In order to value current evidence on damage con-
trol surgery for abdominal surgical emergencies a
PubMed/MEDLINE literature review was recently
published by Weber et al. [116]. Minimal evidence ex-
ists to validate the benefits of damage control surgery
in general surgical abdominal emergencies. The evi-
dence over the past decade is limited to 16 studies in-
cluding a total of 455 patients, of which the majority
are retrospective case series. Damage control surgery
has been performed for a wide range of indications,
but most frequently for uncontrolled bleeding during
elective surgery, hemorrhage from complicated gastro-
duodenal ulcer disease, generalized peritonitis, acute
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mesenteric ischaemia, and other sources of intra-
abdominal sepsis.
The concept of damage control surgery has been ac-
cepted by emergency surgeons and may be a logical ex-
tension from pathophysiological principles in trauma to
hemorrhage and sepsis as life-saving tactic in emergency
surgery performed on physiologically deranged patients.
However, the benefits of this strategy are not clear from
the literature.
Statement 17
Damage control surgery may be an option in se-
lected significantly physiologically deranged patients
with ongoing sepsis (Recommendation 2 C).
Damage control surgery was initially developed in the
1980s by Stone et al. [117] and detailed by Burch et al. in
the early 1990s [118]. Damage control surgery strategy
was defined as the abbreviated laparotomy for trauma pa-
tients with the initial control of surgical bleeding by sim-
ple operative techniques such as packing as life-saving
techniques. The patient was taken to the ICU where sub-
sequent resuscitation corrected hypothermia, acidosis, and
coagulopathy [118]. In severe abdominal sepsis, damage
control surgery using an open abdomen strategy may
allow early draining of any residual infection and control
any persistent source of infection, preventing abdominal
compartment syndrome and deferring definitive interven-
tion and anastomosis until the patient is hemodynamically
stable and thus better able to heal [119]. The concept of
damage control surgery may be easily adapted in patients
with advanced sepsis and can incorporate the principles of
the Surviving Sepsis Campaign (SSC) [71]. Even if little
evidence exists, damage control surgery is employed in a
wide range of abdominal emergencies and may be an in-
creasingly recognized life-saving strategy in emergency
surgery performed on physiologically deranged patients
[119]. However, the role of the OA in the management of
severe peritonitis is still being debated [120]. Robledo et
al. compared open versus closed abdomen procedures in
40 patients with severe secondary peritonitis. They found
no significant difference in mortality rates (55% open ver-
sus 30% closed). Nevertheless, the relative risk and odds
ratio for death in the closed versus open group (1.83 and
2.85, respectively) led to termination of the study at the
first interim analysis. However, in that study, the tempor-
ary abdominal closure was accomplished by a sandwich
technique with non-absorbable mesh sutured to the fascia.
Current clinical guidelines suggest that open abdomen
technique should not be used routinely but should be
individualized for each patient with abdominal sepsis [121,
122]. However, the benefits of this strategy are not yet
clear from the literature.
Statement 18
Temporary abdominal closure using negative pres-
sure therapy (NPT) can be useful to decrease the
time to definitive abdominal closure (Recommenda-
tion 1 B). Prolonged NPT may increase the risk of
enteric fistulae.
Following re-exploration, the goal is early and defini-
tive closure of the abdomen, in order to reduce the com-
plications associated with an open abdomen, such as
entero-atmospheric fistulas, fascial retraction with loss
of abdominal wall domain, and development of massive
incisional hernias. Early definitive closure is the basis for
preventing or reducing the risk of these complications
[123, 124] and should be the goal when the patient’s
physiological condition allows. The literature suggests a
bimodal distribution of primary closure rates. Early
closure depends on post-operative intensive care man-
agement, and delayed closure depends on the choice of
the temporary abdominal closure technique [125]. The
first mode is to close within 4–7 days and achieve a
high rate of primary closure, the second mode has a
delay (20–40 days) having lower overall closure rate
[125]. If a surgeon is unable to close the abdomen early,
the use of a progressive closure device may be neces-
sary. A systematic review and meta-analysis of the open
abdomen and temporary abdominal closure techniques
in non-trauma patients was recently published [126].
The search identified 74 studies comprising 4358 pa-
tients of whom 3461 (79%) had peritonitis. The best re-
sults achieved for delayed fascial closure and reduced
the risk of entero-atmospheric fistula were shown for
NPT with continuous (mesh-mediated) fascial traction.
However, authors stated that the overall quality of the
available evidence was poor and that uniform recom-
mendations cannot be made.
To determine whether active negative pressure peri-
toneal therapy (NPPT) with the ABThera temporary ab-
dominal closure device reduces systemic inflammation
after abbreviated laparotomy, a single-center, random-
ized controlled trial was performed by Kirkpatrick [127].
Forty-five adults with abdominal injury (46.7%) or intra-
abdominal sepsis (52.3%) were randomly allocated to the
ABThera (n = 23) or Barker’s vacuum pack (n = 22). The
cumulative incidence of primary fascial closure at 90 days
was similar between groups. However, the 90-day mor-
tality was less in the ABThera group. Given this poten-
tial survival benefit, further well-powered multicenter
trials should be conducted to confirm these provocative
findings.
When and how do you perform the peritoneal
specimens?
Statement 19
Intraperitoneal specimens for microbiological evalu-
ation from the site of infection are always recom-
mended for patients with HA-IAIs or with CA-IAIs at
risk for resistant pathogens (previous antimicrobial
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therapy) and in critically ill patients (Recommen-
dation 1 B).
Statement 20
Intraperitoneal specimens should be collected in
every re-operation (Recommendation 1 C).
Statement 21
Appropriate intraperitoneal specimen is periton-
eal fluid/tissue collected from the site of infection
(Recommendation 1 C).
Statement 22
Sufficient abdominal fluid/tissue volume (usually
at least 1–2 mL of fluid) should be collected and
transported to the microbiology laboratory using a
transport system that properly handles and pre-
serves the samples to avoid damage or compromise
their integrity (Recommendation 1 C).
Statement 23
At the laboratory the intraperitoneal specimen
should undergo Gram stain, aerobic and anaerobic
culture, and antibiotic susceptibility testing (Recom-
mendation 1 C).
Initial antibiotic therapy for IAIs is empirical in nature
because microbiological data (culture and susceptibility
results) may require >24 h before they are available for a
more detailed analysis. IAIs are often polymicrobial in
etiology. In polymicrobial infections, first the particular
bacterial strains have to be isolated and identified from
intraperitoneal specimen and after that the antibiotic
susceptibility test can be performed. Isolation and identi-
fication of bacterial strains take more time, and results
of antibiotic susceptibility are usually only available after
48 h and later.
However, the results direct expansion of antimicrobial
regimen if it is too narrow and to perform a de-
escalation if it is too broad [128, 129], particularly in
critically ill patients where de-escalation strategy is one
of the cornerstones of antimicrobial stewardship pro-
grams [129]. A lack of impact on patient outcomes by
bacteriological cultures has been documented in patients
with community-acquired IAIs, especially in appendicitis
[130, 131]. Microbiological identification in CA-IAIs
rarely influences the individual patient management.
However, routine bacteriological culture and antibiotic
susceptibility test in patients with CA-IAIs help to detect
epidemiological changes in the resistance patterns of mi-
crobial pathogens associated with CA-IAIs. The results
of microbiological testing may have great importance for
the choice of therapeutic strategy of every patient at risk
for antimicrobial resistance [132]. The recommended
initial antibiotic regimen for risk patients should be de-
termined according to regional epidemiological data and
resistance profile.
The major pathogens involved in CA-IAIs are likely to
be due to a patient’s own flora and are generally
predictable and include Enterobacteriaceae (predomin-
antly Escherichia coli and Klebsiella spp.), viridans group
streptococci, and anaerobes (especially Bacteroides fragilis).
In addition, Enterococcus spp. are frequently isolated
Gram-positive organisms in CA-IAIs with reported per-
centages of 7.7–16.5% [133].
In 2012, the Dutch Peritonitis Study Group analyzing all
patients from the RELAP trial found that the presence of
Gram-positive cocci, predominantly Enterococcus spp.,
was associated with worse outcome, although in second-
ary peritonitis, microbial profiles did not predict ongoing
abdominal infection after initial emergency laparot-
omy [134].
The main current resistance problem is represented by
Extended-spectrum beta-lactamases (ESBLs) producing
Enterobacteriaceae, which are frequently found in CA-
IAIs [135]. Specific risk factors for ESBLs phenotype
among infecting pathogens includes recent exposure to
antibiotics (particularly beta-lactams or fluoroquino-
lones) within 90 days of IAIs or known colonization with
ESBL-producing Enterobacteriaceae. In all HA-IAIs,
causative pathogens are less predictable; thus, peri-
operative cultures are routinely indicated [136, 137].
In a recent retrospective study, data from 242 patients
with secondary peritonitis (88 community acquired, 154
post-operative cases) treated in ICU were obtained.
Enterococci were isolated in 47.1% of all patients,
followed by E. coli (42.6%), and other Enterobacteriaceae
(33.1%), anaerobes (29.8%), and Candida spp. (28.9%).
The susceptibility rates and spectrum adequacy rate
were lower in post-operative than in community-
acquired cases. The spectrum adequacy rate of the most
common regimen used for secondary peritonitis in the
study center, cefotaxime plus metronidazole, was sig-
nificantly different for community-acquired and post-
operative peritonitis episodes, mainly for cases with
polymicrobial positive cultures [138].
Recently, Montravers et al. who evaluated the dynamic
change of microbial flora in persistent peritonitis [12]
observed a progressive shift of peritoneal flora with the
number of reoperations. The proportion of patients har-
boring MDRO strains increased from 41% at index sur-
gery to 49% at the first, 54% at the second (P = 0.037),
and 76% at the third re-operation (P = 0.003 versus index
surgery). Intraperitoneal specimens should be collected
in every re-operation and re-intervention.
Appropriate intraperitoneal specimen is peritoneal
fluid or pus that is collected from the site of infection.
For specimen collection, intraperitoneal fluid, pus, or tis-
sue should be collected in airless sterile syringe with
combi-stopper or in sterile test tube. Intraperitoneal
specimen can be directly inoculated into appropriate
aerobic and anaerobic transport media. Peritoneal swab
and fluid from drain tubes are not recommended
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routinely. Sufficient fluid volume (usually at least 1–
2 mL of fluid or tissue) must be collected, and then
transported to the microbiology laboratory using a trans-
port system that properly handles and preserves the
samples to avoid damage or compromising their integ-
rity [132].
At the laboratory, the intraperitoneal specimen should
be examined under a microscope using Gram stain,
aerobic and anaerobic culture should be established, and
antibiotic susceptibility test should be performed. Re-
ceived peritoneal fluid or pus may be examined under
the microscope immediately because Gram stains may
be of value in detecting Gram-positive cocci or yeast. In
the event of positive finding of Gram-positive cocci or
yeast, the additional empiric anti-cocci or anti-fungi
therapy should be considered before definitive culture
results are available.
When a microorganism is identified in clinical cul-
tures, antimicrobial susceptibility testing (AST) should
always be performed to guide antibiotic therapy.
Results are reported as the minimal inhibitory concen-
tration (MIC), which is the lowest concentration of drug
that inhibits the growth of the organism. Reports typic-
ally contain a quantitative result in μg/mL and a qualita-
tive interpretation. The interpretation usually categorizes
each result as susceptible (S), intermediate (I), and resist-
ant (R) basing on breakpoints established by either the
Clinical or Laboratory Standards Institute (CLSI) in the
USA or the European Committee for Antimicrobial
Susceptibility Testing (EUCAST) in Europe [132].
What are the principles of antimicrobial therapy?
Statement 24
Empirical antimicrobial therapy should be based on
local epidemiology, individual patient risk factors for
difficult to treat pathogens, clinical severity of infec-
tion, and infection source (Recommendation 1 C).
The principles of empiric antibiotic treatment should
be defined according to the most frequently isolated mi-
crobes, always taking into consideration the local trend
of antibiotic resistance.
In this era of prevalent drug-resistant microorganisms,
the threat of resistance is a source of major concern that
cannot be ignored [139].
In the past 20 years, the incidence of IAIs caused by
MDROs has risen dramatically [132].
Quinolone resistance, prevalence of ESBL-producing
bacteria, prevalence and mechanisms of carbapenem re-
sistance in the local environment and the place of recent
traveling should be always taken into account when an
antimicrobial therapy is administered empirically.
Generally, the most important factors in predicting the
presence of resistant pathogens in IAIs is acquisition in
a healthcare setting (particularly if the patient becomes
infected in the ICU or has been hospitalized for more
than 1 week), corticosteroid use, organ transplantation,
baseline pulmonary or hepatic disease, and previous
antimicrobial therapy [136].
Previous antimicrobial therapy is one of the most im-
portant risk factors for resistant pathogens [15].
In order to determine risk factors for presence of
MDROs in post-operative peritonitis (PP), Augustin et al.
reviewed data of 100 patients hospitalized in the ICU for
PP. According to logistic regression analysis, the use of
broad-spectrum antibiotic between initial intervention
and re-operation was the only significant risk factor for
emergence of MDROs [15]. For patients with severe sepsis
or septic shock, early and properly administered empirical
antimicrobial therapy can have a significant impact on the
outcome, independent of the anatomical site of infection.
Riché et al. [140] in a prospective observational study
involving 180 consecutive patients with secondary gener-
alized peritonitis demonstrated a significantly higher mor-
tality rate for patients in septic shock (35 and 8% for
patients with and without shock, respectively). Clinical se-
verity should be assessed with the sepsis score criteria or
the new proposed criteria for definition of sepsis [19].
Inappropriate therapy in critically ill patients may have
a strong negative impact on outcome. An ineffective or
inadequate antimicrobial regimen is one of the variables
more strongly associated with unfavorable outcomes in
critically ill patients. Broad empiric antimicrobial therapy
should be started as soon as possible in patients with
organ dysfunction (sepsis) and septic shock [141–145].
International guidelines for the management of sepsis
and septic shock (the Surviving Sepsis Campaign) recom-
mend intravenously administered antibiotics as soon as
possible and in any case within the first hour of onset of
sepsis and the use of broad-spectrum agents with adequate
penetration of the presumed site of infection [71].
Finally, selection of empirical therapy should take into
account the infection source because etiological distribu-
tion varies according to the source site, with a prevalence
of Gram positive and Candida in the high gastrointestinal
tract and a progressive increase of anaerobes and Gram
negative towards the lower gastrointestinal tracts.
The epidemiology of intra-abdominal flora in critically
ill patients with secondary and tertiary abdominal sepsis
was studied by de Ruiter et al. [146]. A 5-year prospect-
ive observational cohort study was performed in patients
admitted to the ICU with abdominal sepsis syndrome,
defined as a perforation of the digestive tract and inflam-
matory response with organ failure. Abdominal fluid was
taken for microbial culture from 221 of the 239 patients
admitted with abdominal sepsis. Aerobic Gram-negative
bacteria (AGNB) were found in 53% of the cultures of
the abdominal fluid taken at the time of operation, of
which 45% were E. coli; in 36% of patients, more than
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one AGNB was found. The incidence of AGNB was the
highest in colorectal perforations (68.6%) and perforated
appendicitis (77.8%) and the lowest in gastroduodenal
perforations (20.5%). Gram-positive bacteria were
found in 42.5% of the abdominal fluid cultures and
most frequently in colorectal perforations (50.0%).
Candida was found in 19.9% of patients, with 59.1% of
these cultures being Candida albicans. The incidence
of Candida was 41.0% in gastroduodenal perforations
and 11.8% in colorectal perforation. Anaerobic bac-
teria were cultured in 77.8% of patients with perfo-
rated appendicitis. Over time, the prevalence of AGNB
in abdominal fluid decreased from 117 patients
(52.9%) in the first culture to one patient (6.7%) in
week 4 (efficacy 87%). The prevalence of Gram-
positive bacteria increased from 42.5 to 86.7% in a 4-
week period.
Statement 25
The correct dose and correct administration of
antimicrobials should include: 1) loading dose
when indicated, especially in critically ill patients;
2) extended or prolonged infusion for beta-lactam
antibiotics; 3) peritoneal distribution (Recommen-
dation 2 C).
To ensure timely and effective administration of
antimicrobial therapy in patients with severe infec-
tion, clinicians must consider also the pharmacoki-
netic/pharmacodynamics properties of the employed
antibiotics.
The “dilution effect,” also known as the “third spacing
phenomenon,” is very important for hydrophilic agents.
Higher than standard loading doses (LD) of hydrophilic
agents such as beta-lactams should be administered to
ensure optimal exposure at the infection site, maintaining
a therapeutic threshold that considers the effects of renal
function [94].
In patients with sepsis and septic shock, missing of LD
results in an under exposure to hydrophilic antibiotics
that may be critical for patients [147, 148].
Once appropriate initial loading is administered, daily
reassessment of the antimicrobial regimen is warranted
because pathophysiological changes may significantly
affect drug availability [132].
The mechanisms of action of antibiotics should also
be taken into account in establishing the maintenance
dose. Some antibiotics, including beta-lactam antibiotics,
exhibit time-dependent activity and exert optimal bac-
tericidal activity when drug concentrations are main-
tained above the Minimum Inhibitory Concentration
(MIC), whereas high peak concentrations are not benefi-
cial. As a consequence, the more prolonged the time
during which the drug levels are above the MIC value,
the greater is the chance of clinical cure. In fact, pro-
longed or continuous infusions of beta-lactams have
been proposed in order to maximize the time that the
drug concentration exceeds the MIC.
However, the results obtained from clinical studies on
the continuous or extended infusion of beta-lactams,
including two blinded multicenter RCTs, were not con-
clusive [149, 150]. The first RCT, of 60 patients, showed
that continuous infusion (CI) was associated with
higher clinical cure, while the second one, of 432 pa-
tients, did not find significant differences in the clinical
cure of patients receiving CI or intermittent adminis-
tration of beta-lactams. This difference could be par-
tially explained by the enrollment of patients on renal
replacement therapy in the second RCT.
In addition, these results may not be generalizable to
patients with high severity of illness and infections
caused by less susceptible pathogens with high MIC for
which the greatest potential for a clinically relevant
benefit may be predicted by pharmacokinetic/pharmaco-
dynamic theory. This has been supported by some retro-
spective studies [151, 152]. Prolonged or continuous
infusions of beta-lactams should therefore be considered
for the treatment of critically ill patients with HAI-IAIs.
Conversely, for antibiotics with concentration dependent
activity, such as aminoglycosides, the use of a higher dose
at extended interval (i.e., once daily) is strongly recom-
mended [153].
The use of therapeutic drug monitoring (TDM) has
been associated with higher clinical success and lower rate
of toxicity. It is recommended mainly, but not only, for
drugs with a narrow ratio between efficacy and toxicity,
such as glycopeptides and aminoglycosides [154].
Antimicrobials typically need to reach a site of ac-
tion outside the plasma passing through the capillary
membranes. Disease- and drug-related factors contrib-
ute to differential tissue distribution [155]. Concentra-
tion gradient between the plasma and the peritoneal
space may be of high relevance in case of multidrug-
resistant bacteria. It has been studied for some antibi-
otics and has shown large variability in drug availabil-
ity. Data suggest that increased doses of ceftazidime,
meropenem, and imipenem are required to reach ad-
equate concentrations in patients with severe intra-
abdominal infections [156–158]. In contrast, plasma
and peritoneal concentrations of cefepime and cefotax-
ime seem to be quite similar and an increase in the
doses is probably not required [159, 160]. The same
concept can be applied for tigecycline with lipophilic
characteristics that are minimally impacted by severe
intra-abdominal infections [161].
Statement 26
The patient should be reassessed when the re-
sults of microbiological testing are available.
Antimicrobial de-escalation or withdrawal should
be considered (Recommendation 1C).
Sartelli et al. World Journal of Emergency Surgery  (2017) 12:22 Page 12 of 31
The results of microbiological testing may have great
importance for the choice of therapeutic strategy of
every patient, in particular in the adaptation of targeted
antimicrobial treatment.
They provide an opportunity to expand antimicrobial
regimen if the initial choice was too narrow but also
allow de-escalation of antimicrobial therapy if the em-
pirical regimen was too broad.
Antibiotic de-escalation has been associated with
lower mortality rates in ICU patients and is now con-
sidered a key practice for antimicrobial stewardship
purposes [129].
Recently, Montravers et al. [128] valued the characteris-
tics and outcomes of anti-infective de-escalation during
healthcare-associated IAIs. They demonstrated that de-
escalation is a feasible option in patients with polymicro-
bial infections such as HAI-IAIs. However, MDR non-
fermenting Gram-negative organisms limit its implemen-
tation in the setting of IAIs.
Statement 27
In the settings with a high incidence of ESBL-
producing Enterobacteriaceae, the extended use of
cephalosporins should be discouraged and should be
limited to pathogen-directed therapy because of its se-
lective pressure resulting in emergence of resistance
(Recommendation 1C).
In the past, cephalosporins have often been used in
the treatment of IAIs. In light of the increasing preva-
lence of ESBL-producing Enterobacteriaceae and MRSA
due to selection pressures related to overuse of cephalo-
sporins, the routine use of these antibiotics should be
strongly discouraged [162].
Ceftolozane/tazobactam [162, 163] and ceftazidime/
avibactam [164, 165] are two new cephalosporins/beta-
lactamase inhibitor combinations approved for IAIs.
By adding beta-lactamase inhibitor (tazobactam or
avibactam), ceftozolane and ceftazidime have a strong
activity against Gram-negative MDROs including ESBL-
producing Enterobacteriaceae.
These new agents should be combined with metro-
nidazole for complicated IAIs due to limited activity
against some Bacteroides spp. These antibiotics will be
valuable for treating infections caused by Gram-negative
MDROs in order to preserve carbapenems. Notably, cef-
tazidime/avibactam has demonstrated consistent activity
against Klebsiella pneumoniae carbapenemases (KPCs)
producers and ceftolozane/tazobactam against multire-
sistant Pseudomonas.
Cautious clinical use is advised, until their precise
roles are further defined as empirical treatment.
Statement 28
Extended use of fluoroquinolones (FQ) should be
discouraged because of its selective pressure (mainly
ESBLs producing Entrobacteriaceae and MRSA).
They should be generally used in patients with al-
lergy to beta-lactams (Recommendation 1C).
FQ have been the most commonly used regimen for
complicated IAIs in recent years.
Except for moxifloxacin, FQ have a moderate activity
against anaerobes and have been used in combination
with metronidazole in the empiric treatment of IAIs. In
recent years, resistance of E. coli to FQ has risen over
time [166].
The worldwide increase in FQ resistance among E. coli
and other Enterobacteriaceae has limited the non-
stratified use of FQ for empirical treatment of IAIs, par-
ticularly in critically ill patients and those with HAI-IAIs.
Ciprofloxacin, in combination with metronidazole,
should be administered only in patients with mild infec-
tion and without risk factors for difficult to treat patho-
gens (DTTPs). In these patients, moxifloxacin
monotherapy could be an option [167, 168].
What is the impact of the antimicrobial resistance
in IAIs. How do you treat it?
Statement 29
For patients with CA-IAIs, agents with a narrower
spectrum of activity should be suggested. However, ac-
cording to local ecology anti-ESBL-producer coverage
may be warranted. By contrast, for patients with HA-
IAIs, antimicrobial regimens with broader spectra of ac-
tivity are preferred (Recommendation 1B).
Hospital-acquired IAIs are associated with an in-
creased likelihood of pathogens with reduced suscepti-
bility to standard antibiotic regimens. In particular, the
group of patients with IAIs suffering from resistant
bacteria frequently comprises the entire group of post-
operative and tertiary peritonitis. According to local
bacterial ecology, resistant pathogens can be fre-
quently isolated even in community-acquired secondary
peritonitis [170].
In the context of IAIs, the main resistance problem is
posed by ESBL-producing Enterobacteriaceae, which are
alarmingly prevalent in nosocomial infections and fre-
quently observed in community-acquired infections
[169–171]. A Carbapenem-sparing regimen is preferred.
The Study for Monitoring Antimicrobial Resistance
Trends (SMART) program monitors the activity of anti-
biotics against aerobic Gram-negative IAIs.
The prevalence of ESBLs in patients with IAIs has in-
creased over time in Asia, Europe, Latin America, the
Middle East, North America, and the South Pacific. In
contrast, the trend for ESBLs in intra-abdominal infec-
tion isolates from Africa has surprisingly, statistically de-
creased over time [172].
KPC producers are rapidly emerging as a major
source of multidrug-resistant infections worldwide. The
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recent emergence of carbapenem resistance among
Enterobacteriaceae poses a considerable threat to hos-
pitalized patients [173]. Inappropriate use of carbapenems
should be avoided to reduce their selective pressure and
association with the increase in carbapenem-resistant
Enterobacteriaceae (CRE) [174].
Statement 30
Carbapenem sparing treatment should be recom-
mended particularly in the settings where there is
a high incidence of carbapenem resistant K. pneu-
moniae (Recommendation 1B).
The available therapeutic options for the multiresistant
Gram-negative bacteria are limited.
In recent years, clinicians have become dependent on car-
bapenems for treating ESBL infections. This emphasizes
the importance of carbapenem-preserving antimicrobial
stewardship [162].
The role of β-lactam/β-lactamase inhibitor (BLBLI)
combinations towards ESBLs has been debated and con-
troversial even if recent reports suggest their use in
ESBL infections [175, 176].
Although tigecycline does not feature in vitro activity
against P. aeruginosa or certain Enterobacteriaceae
(Proteus spp., Serratia spp., Morganella morganii, Pro-
videncia stuartii), it is still an option for complicated
IAIs because of its favorable in vitro activity against
anaerobic organisms, enterococci, several ESBLs, and
some strains of carbapenemase-producing Enterobacte-
riaceae [177, 178]. Because of poor plasma concentra-
tions, tigecycline performs poorly in bacteremic
patients, with a much higher risk of failing to clear
bacteremia [179]. Tigecycline should not be considered
as first-line therapy in patients with healthcare-
associated pneumonia and bacteremia.
The recent challenges in the management of Gram-
negative MDROs infections, especially in critically ill
patients, have revived the clinical use of polymyxins
[180–182] and fosfomycin [183]. There are still open
questions about the need of combination therapy and
the role of carbapenems, administered at high doses and
by extended infusions, in the treatment of infections
with carbapenem-resistant entetobacteriaceae.
Ceftolozane/tazobactam and ceftazidime/avibactam
have recently been approved in some national agencies
for the treatment of IAIs [162–165]. Ceftolozone/tazo-
bactam is a new antibiotic that has been approved for
treatment of cIAIs (in combination with metronidazole)
including infection by ESBLs and P. aeruginosa and as-
sociated with metronidazole may be valuable for treat-
ing infections caused by Gram-negative MDROs in
order to preserve carbapenems [162, 163]. It may be
useful as empirical therapy to preserve the use of carba-
penems in critical patients with risk factors for ESBL
isolation or as targeted therapy in patients with
isolation of an ESBL-producing enterobacteriaceae or P.
aeruginosa MDR. It should be considered that in some
countries, the production of metallo-β-lactamases en-
zymes, that are not inactivated by ceftolozane/tazobactam,
may be one of the mechanisms for carbapenem resistance
in P. aeruginosa.
Statement 31
Antimicrobial resistance among enterococcal iso-
lates (ampicillin, gentamcin or vancomycin resist-
ance) is mostly found in nosocomial (postoperative or
tertiary) peritonitis. In Vancomycin-resistant Entero-
coccus (VRE), treatment with linezolid (monomicro-
bial infection) or tigecycline (polymicrobial infection)
is appropriate (Recommendation 1 B).
Among Gram-positive bacteria, Enterococci play a
significant role in IAIs. Although they are found in
community-acquired infections, they were far more
prevalent in hospital-acquired infections [184]. In the
CIAOW Study [169], Enterococci (E. faecalis and E.
faecium) were the most prevalent bacteria among all
the aerobic Gram-positive bacteria isolated in the
intra-operative samples, representing 15.9% of all aer-
obic isolates. Although Enterococci were also present
in community-acquired infections, they were more
prevalent in HA-IAIs (22.3% in HA-IAIs versus 13.9%
in CA-IAIs). Some studies have demonstrated poor
outcomes among patients with documented entero-
coccal infections [185–188], particularly in those with
post-operative IAIs where Enterococci coverage
should always be considered. Empirical coverage of
Enterococci is not generally recommended for patients
with CA-IAIs. The acquisition of glycopeptide resist-
ance by enterococci has seriously affected the treatment
and control of these organisms. Many factors can increase
the risk of vancomycin-resistant Enterococcus (VRE) infec-
tion. These include previous antibiotic therapy, prolonged
hospitalization, hospitalization in an intensive care unit, se-
vere illness or underlying pathology, invasive procedures,
gastrointestinal surgery, organ transplantation, and close
proximity to other VRE-positive patients [189].
The majority of vancomicyn-resistant enterococcus
infections have been attributed to E. faecium, though
glycopeptide resistance occurs in E. faecalis and other
Enterococcus spp. as well [189].
Options for treating vancomicyn-resistant entero-
coccus infections are linezolid or tigeciclyine [178, 190].
What is the impact of intra-abdominal candidiasis?
When and how do you treat intra-abdominal
candidiasis?
Statement 32
The presence of Candida spp. in the peritoneal
samples is a factor of poor prognosis (Recommenda-
tion 1C).
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The epidemiological role of Candida spp. in IAI has
not yet been conclusively defined.
Colonizing strains of C. albicans are normally present
in small or moderate numbers and they are only
regarded as part of the resident gastrointestinal micro-
flora [191].
However, isolation of Candida spp. in samples from
IAIs is associated with poor outcomes [192].
In community-acquired infections, the role of
Candida spp. in the prognosis is difficult to demon-
strate. In healthcare-associated (mainly post-operative)
peritonitis, intra-abdominal candidiasis is associated
with increased mortality.
In an observational study, Montravers et al. [193]
showed that isolation of Candida spp. was an independent
risk factor of mortality in nosocomial peritonitis patients.
However, antifungal treatment did not improve survival.
Several criteria have been considered as factors of
poor prognosis for patients with Candida isolation in
peritoneal fluid.
In a retrospective review of a prospective surgical ICU
database of patients, Dupont et al. [194] demonstrated
that four variables were independently associated with
mortality in polymicrobial peritonitis with Candida isola-
tion in peritoneal fluid in critically ill patients. These
were (1) APACHE II (Acute Physiology and Chronic
Health Evaluation II) score on admission of at least 17,
(2) respiratory failure on admission, (3) upper gastro-
intestinal tract origin of peritonitis, and (4) results of dir-
ect examination of peritoneal fluid that were positive for
Candida.
Data from 13 hospitals in Italy, Spain, Brazil, and
Greece over a 3-year period (2011–2013) including pa-
tients from ICU, medical, and surgical wards with intra-
abdominal candidiasis was published in 2015 [195]. A
total of 481 patients were included in the study. Of
these, 27% were hospitalized in ICU. The mean age was
63 years, and 57% of patients were male. Multivariate lo-
gistic analysis regression showed that age, increments in
1-point APACHE II scores, secondary peritonitis, septic
shock, and non-adequate abdominal source control were
significantly associated with mortality. In patients with
septic shock, absence of source control resulted in mor-
tality rates above 60% irrespective of administration of
an adequate antifungal therapy.
Moreover, a prospective observational study involving
180 consecutive patients with secondary generalized
peritonitis (community-acquired and post-operative) at a
single center was published by Riché et al. [140]. Septic
shock complicating intra-abdominal candidiasis was
associated with high mortality rates. Yeast in the peri-
toneal fluid of post-operative peritonitis were an inde-
pendent risk factor for death in patients with septic
shock.
Statement 33
Two situations justify an empirical antifungal
therapy: patients with septic shock in community-
acquired infections or patients with post-operative
infections (Recommendation 2 C).
No study has specifically evaluated the efficacy of anti-
fungal therapy in IAIs. In recent randomized trials fo-
cusing on antifungal therapy of invasive candidiasis, the
proportion of patients with a diagnosis of abdominal
candidiasis was low [196, 197]. The need for an early ad-
equate systemic antifungal therapy in candida peritonitis
is based on the assumption that delayed antifungal
therapy initiation is associated to poorer outcome, par-
ticularly among those with candidaemia [198–200].
However, a deleterious impact of delayed systemic anti-
fungal therapy initiation has never been demonstrated in
candida intra-abdominal infection.
Two situations justify an empirical antifungal therapy:
patients with septic shock in community-acquired infec-
tions or patients with post-operative infections where
the presence of yeast is associated with a poor prognosis.
The EUCAST guidelines consider Candida glabrata
resistant to azole agents [201]. These organisms were
observed in 22% of all intra-abdominal candidiasis in
Montravers et al.’s prospective study. This was a non-
interventional study in 271 adult ICU patients with
proven invasive Candida infection who received sys-
temic antifungal therapy [193]. As a consequence, an
echinocandin should probably be used as empirical anti-
fungal therapy in critically ill patients having CA-IAIs or
HAI-IAIs. First-line fluconazole therapy is preferable in
the other cases. The optimal duration of definitive treat-
ment is not established. The IDSA guidelines did not
provide any recommendations for duration of therapy
[202]. For severe bacterial healthcare-associated IAIs, a
duration of antibacterial therapy between 7 and 15 days
is recommended [203]. Based on the high rates of recur-
rence and relapse in candida IAIs, longer duration has
been recommended by experts (around 2 to 3 weeks)
[195]. De-escalation of empirical antifungal therapy is a
safe procedure as illustrated recently in two studies. In a
recent study, 835 non-neutropenic adults were recruited
in the multicenter prospective observational Amar-
CAND2 study. Patients receiving systemic antifungal
therapy for a documented or suspected invasive candid-
iasis in the ICU and who were still alive 5 days after an-
tifungal initiation were selected [204]. Among the 647
studied patients, early de-escalation at day 5 after anti-
fungal initiation occurred in 142 patients (22%). Early
systemic antifungal therapy (SAT) de-escalation was the
sole factor not associated with increased 28-day mortality
(RR 1.12, 95% CI 0.76–1.66). In non-neutropenic critically
ill adult patients with documented or suspected invasive
candidiasis, SAT de-escalation within 5 days was not
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related to increased day 28 mortality but was associated
with decreased SAT consumption. These results suggest,
for the first time, that SAT de-escalation may be safe in
these patients. In a recent study by Montravers et al. [126]
on 206 patients with HCAI-IAIs, de-escalation was per-
formed in 53% of the cases including antifungal agents in
49% of the cases having antifungal therapy. De-escalation
was not a risk factor for mortality.
What is the optimal duration of antimicrobial
therapy?
Statement 34
In the setting of uncomplicated acute cholecystitis
and acute appendicitis post-operative antimicrobial
therapy is not necessary (Recommendation 1A).
In the event of uncomplicated IAIs, the infection in-
volves a single organ and does not extend to the periton-
eum. When the source of infection is treated effectively
by surgical excision, post-operative antimicrobial therapy
is not necessary, as demonstrated in managing uncom-
plicated acute appendicitis or cholecystitis [3–5].
Statement 35
In patients with IAIs, when patients are not se-
verely ill and when source control is complete, a
short course (3–5 days) of post-operative therapy
is suggested (Recommendation 1A).
Recently, a prospective study on appropriate duration
of antimicrobial therapy was published [6]. The study
randomized 518 patients with IAIs and adequate source
control to receive antibiotics until 2 days after the reso-
lution of fever, leukocytosis, and ileus, with a maximum
of 10 days of therapy (control group), or to receive a
fixed course of antibiotics (experimental group) for 4 ± 1
calendar days.
In patients with intra-abdominal infections who had
undergone an adequate source control procedure, the out-
comes after fixed-duration antibiotic therapy (approxi-
mately 4 days) were similar to those after a longer course
of antibiotics (approximately 8 days) that extended until
after the resolution of physiological abnormalities. In this
study, most patients were not severely ill.
Statement 36
In patients with ongoing or persistent IAIs, the de-
cision to continue, revise, or stop antimicrobial ther-
apy should be made on the basis of clinician
judgment and laboratory information (Recommenda-
tion 1 A).
The high mortality associated with abdominal sepsis
requires clinicians to maintain a high index of clinical
suspicion of treatment failure and the early diagnosis of
ongoing infections. These patients should always be
monitored carefully including the potential use of in-
flammatory response markers.
The most studied biomarkers in clinical settings are
the acute phase proteins (CRP) and procalcitonin (PCT)
[205, 206].
Recently, PCT has been suggested as a novel bio-
marker that may be useful in guiding therapeutic deci-
sion making in the management of sepsis. It may be a
helpful tool to determine the timing and appropriateness
of escalation of antimicrobial therapy in sepsis. A sys-
tematic review and meta-analysis on PCT-guided ther-
apy in ICU patients with severe sepsis and septic shock
was published in 2013 [207]. Seven randomized studies
comprising a total of 1075 patients with severe sepsis or
septic shock were included in the meta-analysis. Both
hospital mortality and 28-day mortality were not different
between PCT-guided therapy and standard treatment
groups. However, duration of antimicrobial therapy was
significantly reduced in those using PCT-guided therapy.
In 2015, a review on PCT-guided antibiotic therapy for
septic patients in the surgical ICU confirmed the benefits
of using procalcitonin including cost-effectiveness and
timing of termination of antibiotics [208].
However, these results were not confirmed in a pro-
spective study in the setting of patients having only IAIs
[209]. In this study including 101 consecutive patients
with peri-operative septic shock secondary to intra-
abdominal infection, PCT decrease to 0.5 ng/mL lacked
sensitivity to predict the treatment response. In addition,
a decrease of at least 80% from the peak level failed to
accurately predict treatment response. PCT may become
a valuable weapon for predicting treatment response.
However, its role has not been defined in cIAIs and
should always be correlated with clinician judgment.
Which interventions improve antibiotic
prescribing practices for patients with IAIs?
Interventions to improve antibiotic prescribing practices
for patients with IAIs should be directed at two different
levels:
1. Patient level—which includes clinical severity,
epidemiological exposures, PK/PD factors,
comorbidities, prior antibiotic exposure, prior
infection, or colonization with MDROs and
infection source
2. Hospital level—including presence of in-hospital
antimicrobial stewardship programs, availability of
local guidelines and updated microbiological data,
infection control policy, educational activities, and
structural resources (like computer-assisted
order entry)
Significant data supports the importance of antibiotic
prescribing practices for patients with IAIs, in critically
ill and non-critically ill patients and in community and
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hospital-acquired infections. Prescribing practices may
influence the outcome and cost of treatment as well as
the risk of superinfection and resistant pathogens in the
individual patient and the broader environment. Compo-
nents of antibiotic prescribing practices that may influence
outcome and the risk of developing superinfection and
antibiotic resistant infections include (a) adequacy of em-
piric antibiotic therapy, (b) the time to initial antibiotic
therapy, (c) appropriate pharmacokinetic dosing, (d) de-
escalation of antibiotic therapy, (e) length of treatment,
and (f) avoidance of unnecessary antibiotic therapy.
Statement 37
Multifaceted interventions are more likely to im-
prove antibiotic prescribing practices than simple,
passive interventions. Didactic educational pro-
grams alone are generally ineffective. (Recommen-
dation 1B).
Most studies of the implementation of guidelines and
prescribing practices, including for IAIs, have involved
multifaceted interventions [210–214]. A longitudinal
study of a multifaceted program that included locally de-
veloped, unit-specific protocols, computer-assisted order
entry, and ICU-based pharmacist facilitation in both a
trauma and a surgical ICU, demonstrated compliance
with protocols and a sustained reduction in multidrug-
resistant pathogens [212]. Popovski et al. performed a
before-and-after study that examined multifaceted inter-
ventions to optimize antibiotic use for IAIs [214]. Inter-
ventions included (1) adapting published guidelines
based on local susceptibility data with stratification of
infection type, (2) creation of educational tools, and (3)
educational programs involving multidisciplinary groups.
Antibiotic selection was significantly altered, and the
change persisted for greater than 2 years. However, no
change was noted in the length of treatment. The diffi-
culty of altering prolonged antibiotic therapy is
highlighted by a recent randomized, controlled trial of a
short, fixed duration of antibiotic therapy for IAIs versus
treatment until the resolution of fever, leukocytosis, and
ileus in which both the control and treatment groups
had substantial non-compliance with significant ex-
tended antibiotic therapy (24 and 18%, respectively) [6].
Statement 38
As a single intervention, implementation of locally
adapted, interdisciplinary evidence based guidelines
that incorporate risk stratification (severity and CA-
IAIs versus HA-IAIs) and local resistance data most
consistently improves components of AB prescribing
for IAI (Recommendation 1 B).
As an individual component of change, the creation of
locally adapted evidence-based guidelines incorporating
local historical culture data with the involvement of an
interdisciplinary team is strongly supported in the litera-
ture [210, 213, 214]. The presence of pre-existing locally
developed antibiotic protocols was independently associ-
ated with improved time to antibiotic treatment and with
survival in a 1-month prospective observational trial of 41
French ICUs [215]. An intra-abdominal source of infection
accounted for 21% of all infection episodes receiving new
antibiotic therapy. Several studies have demonstrated the
ability to achieve a high percentage of adequate empiric
coverage for IAIs employing this approach (Leone 89%,
Raymond 100%, Barie 94%) [216–218].
Statement 39
Computer-assisted order entry, non-physician
healthcare provider facilitation, and therapeutic
drug monitoring can improve components of anti-
biotic prescribing practices, if resources are avail-
able (Recommendation 2 B).
Computerized decision support programs and
computer-assisted implementation methods have been
found to be useful in many studies of antibiotic therapy
[219–221]. In one cluster randomized trial of three hos-
pitals from Israel, Germany, and Italy, a computerized
decision support system significantly increased the rate
of appropriate empirical antibiotic treatment of infec-
tions, with an adjusted odd ratio of 1.48 [222].
Computer-based advisors and decision support have
also been used to improve antibiotic dosing in various
populations.
Though seldom examined in isolation, non-physician
healthcare providers, most commonly pharmacists and
nurses, have facilitated guideline implementation and
compliance in most randomized trials and before-and-
after studies [223–225].
Which are the determinants of outcome of
patients with cIAIs in ICU?
Statement 40
The lack of source control and antibiotic adequacy
are the only modifiable risk factors for mortality in
patients with cIAIs admitted to the ICU. Organ dys-
function is associated with worse outcomes (Recom-
mendation 1 B).
Patients with cIAIs present with varying severity of
illness and may require ICU care in the pre or post-
operative periods which may be associated with a high
mortality rate.
Although cIAIs are the second most frequent infection
in the ICU, outcomes after ICU admission and risk fac-
tors have been sparsely studied.
De Waele et al. performed a systematic review of the
literature to identify factors independently associated
with outcome in patients admitted to the ICU because
of cIAIs. Studies were included in the analysis if they
include ICU patients with cIAIs and reported the im-
pact of any clinical treatment or microbiological factor
on outcome. Thirty-two studies, published between
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1999 and 2014, were retrieved and eight were selected
for inclusion in this analysis. In total, 3967 patients
were analyzed in these eight studies, three studies
were single-center studies, and three included fewer
than 200 patients. Two studies did not consider any
surgical characteristic for analysis; source control ad-
equacy was evaluated to some extent in six but details
such as source control timing were only assessed in
two. Half of the studies did not consider antibiotic ad-
equacy as a variable; and timing of antibiotic therapy
was not assessed in any study. Five studies considered
microbiological characteristics as potential factors that
may impact outcome. Reported mortality included ei-
ther ICU mortality or hospital mortality (three each),
and 30-day and 4-month mortality. Risk factors associ-
ated with mortality could be categorized into three
major classes: (1) patient comorbidity, (2) treatment,
and (3) severity of illness. All studies reported severity
of illness (variable expressed, either scoring systems,
organ dysfunction, or need for organ support) as a risk
factor for outcome; Acute Kidney Injury (AKI) was cited
specifically in five studies. Patient characteristics included
age (three studies), gender (one study), and infection
source (two studies). Comorbidities that were associated
with outcome included cirrhosis (three studies) and
hematological cancer (one study). Lack of source control
was reported as independently associated with poor out-
come in three studies; inadequate antibiotic therapy in
one.
Which treatment duration is adequate
for critically ill patients with complicated
intra-abdominal infection? Which are the major
determinants of antibiotic choice in patients with
complicated intra-abdominal infection (cIAI)?
Statement 41
If the patient is critically ill the treatment duration
can be deferred until after a multi-disciplinary care-
ful evaluation (Recommendation 1B).
Inadequate source control and inappropriate antibiotics
are key determinants of mortality in patients having intra-
abdominal sepsis and associated bacteremia.
In order to describe characteristics of critically ill pa-
tients with secondary blood stream infection (BSI) of
intra-abdominal origin and identify predictors of mortal-
ity, a retrospective, single-center study that evaluated pa-
tients admitted between January 2005 and January 2011
was recently published [67]. Logistic regression analysis
revealed inadequate source control (P = 0.002) and in-
appropriate antibiotics (P = 0.016) to be independently as-
sociated with mortality. In non-critically ill patients with
adequate source control procedure after cIAI, the duration
of the antimicrobial therapy was well defined [6]. How-
ever, for critically ill patients, an individualized approach
is always mandatory. Appropriate antibiotic therapy, is a
cornerstone for the success.
Statement 42
Principal determinants of antibiotic choice in crit-
ically ill patients are based on three parameters: 1)
Severity of illness, 2) local ecology, and 3) risk factors
of the host. Previous antibiotic use is associated with
a higher development of multidrug resistant organ-
isms (MDROs). Broad-spectrum antibiotic therapy,
including combination of different antibiotic classes
should be recommended in patients with septic
shock, settings with high rates of MDRO, and previ-
ous antibiotic administration (Recommendation 1B).
Abdominal sepsis is a common indication for ad-
mission to the ICU. In 2014, the EPIC II study [226],
including 13,796 adult patients from 1265 ICUs in 75
countries, demonstrated ICU mortality was higher in
patients with abdominal infections compared to those
with other infections (29.4 vs. 24.4%, P < 0.001). In
patients with septic shock, early appropriate empiric
antimicrobial therapy has a significant impact on the
outcome, independent of the site of infection [227].
Prompt institution of antimicrobial therapy that is ac-
tive against the causative pathogen(s) is crucial in the
treatment of patients with severe infection and sepsis.
In fact, the Surviving Sepsis Campaign strongly rec-
ommends initiating antibiotic therapy within the first
hour of recognition of severe sepsis, after suitable cul-
tures have been obtained. In a retrospective analysis of
a large dataset collected prospectively for the Surviving
Sepsis Campaign, Ferrer et al. [228] demonstrated that
delay in first antibiotic administration was associated
with increased in-hospital mortality in patients with se-
vere sepsis and septic shock.
An antimicrobial policy of de-escalation therapy con-
sisting of the initial use of wide-spectrum antimicro-
bials followed by a reassessment of treatment when
culture results are available should be a principle of
antimicrobial stewardship in critically ill patients [229].
Studies have reported conflicting effects on outcomes
with de-escalation in various groups of critically ill
patients.
To assess the safety and the impact on in-hospital and
90-day mortality of antibiotic de-escalation in patients ad-
mitted to the ICU with severe sepsis or septic shock, a pro-
spective study was published in 2014 [230].
By multivariate analysis, factors independently associ-
ated with in-hospital mortality were septic shock, elevated
SOFA score the day of culture results, and inadequate em-
pirical antimicrobial therapy. In contrast, de-escalation
therapy was a protective factor. However, in 2014, a multi-
center randomized trial investigating a strategy based on
de-escalation of antibiotics resulted in prolonged duration
of ICU stay but did not affect the mortality rate [231].
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Recently, Montravers et al. demonstrated that de-
escalation is a feasible option in patients with polymicro-
bial infections such as healthcare-associated IAIs [128].
In a context of a dedicated “antibiotic stewardship” pro-
gram, de-escalation should be encouraged, whenever
possible, to optimize antibiotic use [232].
Emphasis on MDRO epidemiology is needed to bet-
ter understand current strategies of prevention and
management of critically ill patients in ICUs [233].
A rational use of antibiotics is important in order
to prevent the emergence of multidrug-resistant bac-
teria, especially in ICUs. In critically ill patients, posi-
tive cultures may actually represent contamination.
Antibiotic stewardship for critically ill patients may
be translated into the implementation of specific guide-
lines, which were largely promoted by the Surviving Sepsis
Campaign, targeted to optimizing choice, dosage, and dur-
ation of antibiotics in order to improve outcomes and re-
duce the development of resistance [234, 235].
What is the best management of patients with
abdominal sepsis?
Statement 43
Early identification of sepsis and prompt admin-
istration of intravenous fluids and vasopressors are
always mandatory. Restoring a mean systemic ar-
terial pressure of 65 to 70 mm Hg is a good initial
goal during the hemodynamic support of patients
with sepsis (Recommendation 1 A).
The definition of sepsis (Sepsis-3) [19] has returned
to the traditional views that sepsis is characterized by
organ dysfunction attributed to an infection. Patients
with at least two of three clinical abnormalities in-
cluding Glasgow coma score of 14 or less, systolic
blood pressure of 100 mmHg or less, and respiratory
rate 22/min or greater may have poor outcome typ-
ical of sepsis. Importantly, qSOFA does not define
sepsis but provides simple bedside criteria to screen
adult patients with suspected infection. Sepsis is now
defined as a life-threatening organ dysfunction caused
by a dysregulated host response to infection. It can
be clinically represented by an increase in the SOFA
score of 2 points or more [19]. Norepinephrine is
now the first-line vasopressor agent which is used to
correct hypotension in the event of septic shock. It is
more efficacious than dopamine and is more effective for
reversing hypotension in patients with septic shock [71,
236–238]. Septic shock is defined as a subset of sepsis in
which particularly profound circulatory, cellular, and
metabolic abnormalities who are associated with higher
risk of mortality than with sepsis alone. Patients with sep-
tic shock can be clinically identified by requirement for
vasopressors to maintain a mean arterial pressure of
65 mmHg or greater and serum lactate level less than
2 mmol/L (>18 mg/dL) in the absence of hypovolemia
[19]. Under this terminology, “severe sepsis” becomes su-
perfluous. Sepsis should generally warrant greater levels of
monitoring and interventions.
In patients with sepsis, the 2016 SCC guidelines sug-
gest that initial hemodynamic resuscitation should be
achieved within 3 h [71].
Fluid therapy is needed to improve microvascular
blood flow through an increased cardiac output as an es-
sential part of the treatment of sepsis. A fluid challenge
should incorporate four determinant elements [236]: (1)
crystalloid solutions should be the first choice because
they are well tolerated and cheap; (2) fluids should be in-
fused rapidly to induce a quick response but not so fast
that an artificial stress response develops; (3) the goal
should be an increase in systemic arterial pressure; and
(4) avoidance of pulmonary edema which is the most
serious complication of fluid infusion through appropri-
ate monitoring that is necessary to prevent edema
occurrence.
Hypotension is the most common indicator of inad-
equate perfusion. Restoring a mean arterial pressure of 65
to 70 mmHg is a good initial goal during hemodynamic
support of patients with sepsis [239].
Statement 44
Fluid overload should be avoided in patients with
generalized peritonitis, (Recommendation 1C).
In patients with generalized peritonitis, fluid resuscita-
tion should avoid fluid overload, which may aggravate
gut edema and lead to increased intra-abdominal pres-
sure (IAP) [239].
The systemic inflammatory response syndrome, in-
creased vascular permeability, and aggressive crystalloid
resuscitation predispose to fluid sequestration and col-
lection in the peritoneum. Patients with advanced sepsis
commonly develop bowel edema. These changes along
with an associated forced closure of the abdominal wall
may result in increased IAP ultimately leading to intra-
abdominal hypertension (IAH) [238]. Elevated IAP may
reduce both regional and global perfusion resulting in
significant organ failure. An uncontrolled IAH, with an
IAP exceeding 20 mmHg, and new organ failure onset
leads to abdominal compartment syndrome (ACS). ACS
is a potentially lethal complication affecting splanchnic,
cardiovascular, pulmonary, renal, and central nervous
systems [117, 240].
What are the role of the adjunctive therapies in
sepsis?
Statement 45
There is currently insufficient evidence supporting
the use of any adjunctive therapy in patients with sep-
tic shock due to intra-abdominal infection (No
Recommendation).
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Although source control, antimicrobial therapy, and
supportive therapies remain the cornerstone of treat-
ment, especially in the early phase of sepsis, the identifi-
cation of adjunctive therapies may play an important
role in patients with ongoing sepsis.
In septic patients, mortality is higher when both pro-
and anti-inflammatory cytokine levels are high [241, 242].
The rationale of using extracorporeal blood purification in
patients with septic shock is to modulate the immune re-
sponse. Blood purification for sepsis has consisted of
various techniques: high-volume hemofiltration, high-
adsorption hemofiltration, high cut-off membrane hemo-
filtration, plasma exchange, and hybrid systems [243].
A systematic review and meta-analysis of randomized
trials to determine the association between various blood
purification techniques and all-cause mortality in
humans with sepsis was published in 2013 [244]. Ten
single-center and six multicenter studies were identified.
Ten trials reported patients with either severe sepsis or
septic shock, while five trials reported only patients with
a diagnosis of sepsis. One trial included patients with
sepsis, severe sepsis, or septic shock. The blood purifica-
tion techniques used included hemoperfusion (ten trials),
hemofiltration (four trials), and plasma exchange (two
trials).
Overall, blood purification decreased mortality com-
pared with no blood purification. However, these re-
sults were driven mainly by hemoperfusion. Pooling of
all trials of blood purification for treatment of sepsis
was no longer associated with lower mortality after ex-
cluding trials using polymyxin B hemoperfusion. PMB-
HP has been debated in recent years [245-246]. PMB-
HP represents a promising strategy, but the Franch,
prospective, multicenter, randomized controlled trial
(ABDOMIX group) enrolling 243 patients with septic
shock within 12 hours after emergency surgery for peri-
tonitis related to organ perforation [247] failed to dem-
onstrate a benefit. More recently the EUPRATHES
(evaluating Polymyxin B Hemoperfusion in a random-
ized controlled study of adults treated for endotoxemia
and septic shock) trial of PMB-HP in patients with sep-
tic shock and confirmed endotoxemia also failed to
show an improved survival [248].
The use of intravenous immunoglobulin for treating
patients with surgical sepsis is controversial. It is based
on a potential benefit related to neutralization of endo-
toxin and various bacterial products. Intravenous im-
munoglobulin provides antibodies that can neutralize
circulating exotoxins produced by organisms and may
modulate the systemic inflammatory response induced
by cytokine stimulation [249].
In order to evaluate the effects of intravenous im-
munoglobulin (IVIG) as adjunctive therapy in patients
with bacterial sepsis or septic shock on mortality,
bacteriological failure rates, and duration of stay in
hospital, a Cochrane review was published in 2013
[250]. Forty-three RCTs comparing IVIG (monoclonal
or polyclonal) with placebo or no intervention in pa-
tients of any age with bacterial sepsis or septic shock
were reviewed. Subgroup analysis of ten polyclonal
IVIG trials (n = 1430) and seven trials on IgM-enriched
polyclonal IVIG (n = 528) showed significant reductions in
mortality in adults with sepsis compared to placebo or no
intervention. Pooled analysis of polyclonal and monoclonal
IVIG was not done due to clinical heterogeneity. Polyclonal
IVIG reduced mortality among adults with sepsis however
this benefit was not seen in trials with low risk of bias.
A review of the mechanisms of action and meta-
analysis of the clinical effectiveness was recently pub-
lished [251]. The meta-analysis of 18 RCTs indicated
that the use of IVIG reduces the mortality risk of septic
patients. Low study quality, heterogeneous dosing regi-
mens and type of Ig preparations, and different control
interventions (placebo or albumin) are thought to have
probably influenced results. Thus, the study showed that
the use of IVIG therapy in adult septic patients may
have a rationale and seems to be associated with a re-
duced mortality. However, the available evidence is not
clearly sufficient to support the widespread use of IVIG
in the treatment of sepsis.
A meta-analysis of randomized controlled studies pub-
lished in 2007 compared IVIG preparations [252]. The
meta-analysis demonstrated a strong trend in favor of an
immunoglobulin preparation enriched with IgA and IgM
(IgGAM) compared with preparations containing only
IgG. 2016 Surviving Sepsis Campaign guidelines do not
support the use of IVIG therapy [71].
Which inflammatory mediators are involved in
intra-abdominal sepsis? Are they useful markers
in clinical practice?
Statement 46
Inflammatory biomarkers require further con-
trolled studies before their measurement guides
clinical care of critically ill/injured patients (No
recommendation).
Inflammatory and protein mediators (cytokine, chemo-
kine, acute phase proteins) play an important, but still
not completely understood, role in the morbidity and
mortality of abdominal sepsis.
Their potential utility includes function as (1) diagnos-
tic/prognostic biomarkers, (2) therapeutic targets, and
(3) elucidation of the pathogenic mechanisms of sepsis
or injury-related organ dysfunction.
However, there is no consensus on the clinical use of
mediators in diagnosing or managing intra-abdominal
sepsis or injury. A MEDLINE, PubMed, EMBASE, and
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the Cochrane Library review on inflammatory mediators
in abdominal sepsis was published in 2015 [253].
Serum PCT and C-reactive protein (CRP) appear to be
useful to rule out infection or monitor therapy. There
have been 33 studies exploring CRP as a marker for ab-
dominal infection or complications after surgery. Kinetic
studies demonstrated CRP levels elevate on post-operative
day (POD) 1, peak from POD2 to POD3, and decline by
POD5 provided that there is no complication or infection.
Four reports suggest a persistent threshold of greater than
100 mg/L might indicate abscess/septic complications
[254–257]; other studies have refuted this conclusion,
leaving uncertainty for clinical utility [258–262].
Twelve trials including two randomized controlled
studies evaluated the role of PCT as an indicator to diag-
nose infection, predict outcomes, or guide treatment of
abdominal sepsis.
In some studies, persistent high levels of PCT were as-
sociated with infection and or increased septic mortality
in patients with sepsis [263, 264], while other studies
have not confirmed PCT as an accurate marker for
sepsis or to predict a patient’s response to the initial
treatment [201, 265].
The role of IL-6 as a marker to diagnose sepsis or pre-
dict outcomes has also been studied. However, its role
remains uncertain and a wide range of cut-off values
had been used (from 12 to 2760 pg/mL). Some studies
considered IL-6 an indicator for sepsis or for predicting
outcome and mortality [266–268]. However, other stud-
ies do not support the use of IL-6 as a valid sepsis bio-
marker [269, 270].
Recent studies have reported endogenous DAMPs
(mtDNA, HMGB1) released as a consequence of tissue in-
jury or infection to be promising biomarkers [271, 272];
however, the evidence supporting their role is still limited
and their use undefined.
Statement 47
Consideration should be given to draining ascites in
the critically ill patient treated for peritonitis, espe-
cially if the ascites is associated with IAH (Recommen-
dation 1C).
It has been found that increased levels of both systemic
and peritoneal cytokines are associated with post-
operative complications, which may discriminate survivors
from those who died [273, 274].
These data suggest that measurement of peritoneal
cytokines could be a potentially important method to
determine and follow the patient’s inflammatory
reaction.
Although data from research with animal models [275]
having inflammatory bowel disease [265, 276] are sug-
gestive, direct evidence does not yet exist to prove that ef-
fectively draining this peritoneal fluid makes a difference
to complications or survival.
Severe IAH has been shown to significantly reduce
perfusion to the intestinal mucosa, which ultimately in-
creases intestinal permeability and results in systemic
endotoxemia aggravating the sepsis cascade. Damaged
gut is a continual source of inflammation and MODS,
referred to as the “Motor of MSOF” [277–282], by indu-
cing the production of cytokines and other biomediators.
The release of endotoxin induces production of cyto-
kines, including interleukin (IL)-6, IL-1B, IL-8, tumor
necrosis factor-α (TNF-α), and other mediators and
movement of these mediators into the systemic circula-
tion may be largely modulated by the mesenteric lymph-
atic channels, as demonstrated in animal models [283].
In clinical practice, the accumulation of intraperitoneal
mediators can be removed by either percutaneous drain-
age and negative pressure therapy with an open abdo-
men. Percutaneous drainage is recommended to treat
IAH if it is possible to do safely, as it may obviate the
need for decompressive laparotomy [119, 284]. If percu-
taneous drainage is not safely possible, NPPT may be
another appropriate option.
A single-center RCT published in 2015 conducted on
critically ill and injured patients with an average APA-
CHE score above 22 in critically ill and an ISS over 23
in the injured compared commercial NPPT system with
the Barkers VAC PAC in a randomized fashion [125].
Although this study did not find a difference in actual
peritoneal fluid drainage or in the behavior of the high
level mediators examined (IL-1β, IL-8, IL-10, or IL-12,
p70, or TNFα), there was a survival difference in favor
of the commercial system. However, it is possible that
patient heterogeneity in the complex setting of mixed
critical care populations can alone explain the findings,
and thus, further studies are required.
Conclusions
In the Appendix, all the recommendations from the
“Dublin WSES 2016 Intra-Abdominal Infections Con-
sensus Conference” are listed.
Appendix
Classification, diagnosis, and risk factors
Statement 1
The term “intra-abdominal infections” describes a wide
heterogeneity of clinical conditions. The anatomical extent
of infection, the presumed pathogens involved, risk factors
for major resistance patterns, and the patient's clinical
condition should be assessed independently so as to clas-
sify patients (Recommendation 1 C).
Statement 2
Early clinical evaluation is essential for diagnosing
IAIs. It helps to optimize diagnostic testing and can re-
sult in earlier implementation of a proper management
plan (Recommendation 1C).
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Statement 3
A step-up approach for diagnosis should be used and
tailored to the clinical setting, resources, patient’s age be-
ginning with clinical and laboratory examination and pro-
gressing to imaging examinations (Recommendation 1C).
Statement 4
Patient factors are essential when addressing treatment
outcome, as advanced age, associated comorbidity, pre-
existing disease, and physiologic status greatly influence
outcomes (e.g., mortality) (Recommendation 2 C).
Statement 5
Disease factors are essential to consider when addressing
risk for treatment failure. (Recommendation 2 C).
Statement 6
While age alone is not decisive for outcome it should
be recognized that patients with an accumulated num-
ber of risk factors, including advanced age, high disease
severity and presenting in sepsis or septic shock, have a
very high risk of death. Palliative care should be actively
discussed when conditions indicate that operative treat-
ment is futile (Recommendation 2 C).
Statement 7
Prognostic scoring systems for complicated IAIs may be
useful in clinical practise, especially for audit and research.
Scoring systems can be broadly divided into two groups:
general organ failure severity (ICU) scores and peritonitis-
specific (Surgical) scores. The Sequential Organ Failure
Assessment (SOFA) score allows physicians to follow the
evolving disease process in critically ill patients in ICU
(Recommendation 2 A).
However, although these scores may help guide clinical
care, their use in individual patients is much less
predictive.
Source control
Statement 8
Most patients with cIAIs and sepsis/septic shock should
undergo an urgent source control procedure; source con-
trol can be delayed in less severely-ill patients when the
circumstances are appropriate (Recommendation 2 C).
Statement 9
Highly selected patients with perforated diverticulitis
(including those with an abscess <4 cm in diameter), a
peri-appendiceal mass, or a perforated peptic ulcer can
be managed without definitive source control if responding
satisfactorily to antimicrobial therapy and other supportive
measures. (Recommendation 1 B).
Statement 10
Laparoscopic appendectomy represents the first choice
for most patients with acute appendicitis where appropriate
resources and skills are available (Recommendation 1 A).
Statement 11
There is no evidence of any significant advantages
between laparoscopic and open repair of perforated peptic
ulcer (PPU). However, laparoscopy has less post-operative
pain and shorter hospital stay (Recommendation 1 A).
Statement 12
Early laparoscopic cholecystectomy is safe and feasible
in acute cholecystitis and should be the preferred choice
in absence of contraindications to pneumoperitoneum,
even in high risk patients, where appropriate resources
and skills are available (Recommendation 1A).
Statement 13
Laparoscopic lavage is not recommended in Hinchey
IV diverticulitis because it can not achieve adequate
source control. Laparoscopic lavage is safe and not inferior
to sigmoid resection in case of Hinchey III but it is not
considered the preferred choice, given the lack of evidence
of major benefits (Recommendation 1A).
Statement 14
Laparoscopic sigmoid resection is feasible and safe
in selected patients, hemodynamically stable, without
significant comorbidities and with onset of peritonitis
<12-24 hours, only if specific advanced laparoscopic colo-
rectal expertise is available (Recommendation 2 C).
Statement 15
Planned relaparotomy is not recommended as a
general strategy in patients with secondary peritonitis
(Recommendation 1A).
Statement 16
There is insufficient evidence to advocate damage
control surgery as general strategy in patients with
secondary peritonitis (Recommendation 1C).
Statement 17
Damage control surgery may be an option in selected
significantly physiologically deranged patients with on-
going sepsis (Recommendation 2C).
Statement 18
Temporary abdominal closure using negative pressure
therapy (NPT) can be useful to decrease the time to defini-
tive abdominal closure (Recommendation 1B). Prolonged
NPT may increase the risk of enteric fistulae.
Antimicrobial therapy
Statement 19
Intraperitoneal specimens for microbiological evaluation
from the site of infection are always recommended for pa-
tients with HA-IAIs or with CA-IAIs at risk for resistant
pathogens (previous antimicrobial therapy) and in critic-
ally ill patients (Recommendation 1 B).
Statement 20
Intraperitoneal specimens should be collected in every
re-operation (Recommendation 1 C).
Statement 21
Appropriate intraperitoneal specimen is peritoneal
fluid/tissue collected from the site of infection
(Recommendation 1 C).
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Statement 22
Sufficient abdominal fluid/tissue volume (usually at
least 1–2 mL of fluid) should be collected and trans-
ported to the microbiology laboratory using a trans-
port system that properly handles and preserves the
samples to avoid damage or compromise their integ-
rity (Recommendation 1 C).
Statement 23
At the laboratory the intraperitoneal specimen should
undergo Gram stain, aerobic and anaerobic culture, and
antibiotic susceptibility testing (Recommendation 1 C).
Statement 24
Empirical antimicrobial therapy should be based on
local epidemiology, individual patient risk factors for
difficult to treat pathogens, clinical severity of infec-
tion, and infection source (Recommendation 1 C).
Statement 25
The correct dose and correct administration of antimi-
crobials should include: 1) loading dose when indicated,
especially in critically ill patients; 2) extended or pro-
longed infusion for beta-lactam antibiotics; 3) peritoneal
distribution (Recommendation 2 C).
Statement 26
The patient should be reassessed when the results of
microbiological testing are available. Antimicrobial de-
escalation or withdrawal should be considered (Recom-
mendation 1C).
Statement 27
In the settings with a high incidence of ESBL-producing
Enterobacteriaceae, the extended use of cephalosporins
should be discouraged and should be limited to pathogen-
directed therapy because of its selective pressure resulting
in emergence of resistance (Recommendation 1C).
Statement 28
Extended use of fluoroquinolones (FQ) should be
discouraged because of its selective pressure (mainly
ESBLs producing Entrobacteriaceae and MRSA). They
should be generally used in patients with allergy to
beta-lactams (Recommendation 1C).
Statement 29
For patients with CA-IAIs, agents with a narrower
spectrum of activity should be suggested. However,
according to local ecology anti-ESBL-producer cover-
age may be warranted. By contrast, for patients with
HA-IAIs, antimicrobial regimens with broader spectra
of activity are preferred (Recommendation 1B).
Statement 30
Carbapenem sparing treatment should be recom-
mended particularly in the settings where there is a
high incidence of carbapenem resistant K. pneumo-
niae (Recommendation 1B).
Statement 31
Antimicrobial resistance among enterococcal iso-
lates (ampicillin, gentamcin or vancomycin resistance)
is mostly found in nosocomial (postoperative or ter-
tiary) peritonitis. In Vancomycin-resistant
Enterococcus (VRE), treatment with linezolid (mono-
microbial infection) or tigecycline (polymicrobial in-
fection) is appropriate (Recommendation 1 B).
Statement 32
The presence of Candida spp. in the peritoneal sam-
ples is a factor of poor prognosis (Recommendation 1C).
Statement 33
Two situations justify an empirical antifungal therapy:
patients with septic shock in community-acquired
infections or patients with post-operative infections
(Recommendation 2 C).
Statement 34
In the setting of uncomplicated acute cholecystitis
and acute appendicitis post-operative antimicrobial
therapy is not necessary (Recommendation 1A).
Statement 35
In patients with IAIs, when patients are not severely
ill and when source control is complete, a short
course (3–5 days) of post-operative therapy is sug-
gested (Recommendation 1A).
Statement 36
In patients with ongoing or persistent IAIs, the deci-
sion to continue, revise, or stop antimicrobial therapy
should be made on the basis of clinician judgment and
laboratory information (Recommendation 1 A).
Statement 37
Multifaceted interventions are more likely to improve
antibiotic prescribing practices than simple, passive in-
terventions. Didactic educational programs alone are
generally ineffective.
(Recommendation 1B).
Statement 38
As a single intervention, implementation of locally
adapted, interdisciplinary evidence based guidelines that
incorporate risk stratification (severity and CA-IAIs
versus HA-IAIs) and local resistance data most consist-
ently improves components of AB prescribing for IAI
(Recommendation 1 B).
Statement 39
Computer-assisted order entry, non-physician health
care provider facilitation, and therapeutic drug
monitoring can improve components of antibiotic
prescribing practices, if resources are available
(Recommendation 2 B).
Critically ill patients
Statement 40
The lack of source control and antibiotic adequacy are
the only modifiable risk factors for mortality in patients
with cIAIs admitted to the ICU. Organ dysfunction is
associated with worse outcomes (Recommendation 1 B).
Statement 41
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If the patient is critically ill the treatment duration can
be deferred until after a multi-disciplinary careful evalu-
ation (Recommendation 1B).
Statement 42
Principal determinants of antibiotic choice in critically
ill patients are based on three parameters: 1) Severity of
illness, 2) local ecology, and 3) risk factors of the host.
Previous antibiotic use is associated with a higher de-
velopment of multidrug resistant organisms (MDROs).
Broad-spectrum antibiotic therapy, including combin-
ation of different antibiotic classes should be recom-
mended in patients with septic shock, settings with
high rates of MDRO, and previous antibiotic adminis-
tration (Recommendation 1B).
Statement 43
Early identification of sepsis and prompt administra-
tion of intravenous fluids and vasopressors are always
mandatory. Restoring a mean systemic arterial pressure
of 65 to 70 mm Hg is a good initial goal during the
hemodynamic support of patients with sepsis (Recom-
mendation 1 A).
Statement 44
Fluid overload should be avoided in patients with gen-
eralized peritonitis, (Recommendation 1C).
Statement 45
There is currently insufficient evidence supporting the
use of any adjunctive therapy in patients with septic shock
due to intra-abdominal infection (No Recommendation).
Statement 46
Inflammatory biomarkers require further controlled
studies before their measurement guides clinical care of
critically ill/injured patients (No recommendation).
Statement 47
Consideration should be given to draining ascites in the
critically ill patient treated for peritonitis, especially if the
ascites is associated with IAH (Recommendation 1C).
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